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Summary
Human embryonic stem cells (hESC) are now routinely cultured in 
many laboratories, and differentiation protocols are available to 
generate a large variety of cell types. In an ongoing ethical debate 
opinions of different groups are based on varying sets of religious, 
historical, cultural and scientific arguments as well as on widely 
differing levels of general information. We here give an overview of 
the biological background for non-specialists, and address all is-
sues of the current stem cell debate that are of concern in different 
cultures and states. Thirty-five chapters address embryo definition, 
potential killing and the beginning of human life, in addition to 
matters of human dignity, patenting, commercialisation, and po-
tential alternatives for the future, such as induced pluripotent (re-
programmed) stem cells. All arguments are compiled in a synopsis, 
and compromise solutions, e.g. for the definition of the beginning 
of personhood and for assigning dignity to embryos, are suggested. 
Until recently, the major application of hESC was thought to be 
transplantation of cells derived from hESC for therapeutic use. We 
discuss here that the most likely immediate uses will rather be in 
vitro test systems and disease models. Major and minor pharma-
ceutical companies have entered this field, and the European Un-
ion is sponsoring academic research into hESC-based innovative 
test systems. This development is supported by new testing strate-
gies in Europe and the USA focussing on human cell-based in vitro 
systems for safety evaluations, and shifting the focus of toxicology 
away from classical animal experiments towards a more mecha-
nistic understanding. 
Zusammenfassung: Die biologische und ethische Grundlage für 
die Anwendung embryonaler Stammzellen für in vitro testsysteme 
und Zelltherapie
Humane embryonale Stammzellen (hESC) werden jetzt rou-
tinemäßig in vielen Labors kultiviert, und Differenzierungspro-
tokolle wurden entwickelt, um eine breite Palette unterschiedlicher 
Zelltypen herzustellen. In der derzeitigen ethischen Diskussion 
stützen sich die Meinungen der verschiedenen Parteien auf re-
ligiöse, historische, kulturelle und wissenschaftliche Argumente. 
Ebenfalls tragen unterschiedliche Informationsniveaus zur Bildung 
unterschiedlicher Meinungen bei. Wir geben hier eine Übersicht 
für den Laien über den biologischen Hintergrund und sprechen alle 
Aspekte der gegenwärtigen Stammzelldebatte an, die derzeit die 
Menschen in verschiedenen Ländern und Kulturen bewegen. Fün-
funddreißig Unterkapitel beschäftigen sich mit der Embryodefini-
tion, dem Tötungsaspekt und der Definition des Anfangs des Leb-
ens, aber auch mit Aspekten der Menschenwürde, der Patentierung 
und Kommerzialisierung von Leben und möglichen Alternativen für 
die Zukunft, wie induziert pluripotenten (reprogrammierten) Stam-
mzellen. Alle Argumente wurden synoptisch zusammengestellt. 
Kompromisslösungen z.B. für die Definition des Anfangs der Men-
schwerdung und für den Status der Menschenwürde von Embryos 
werden präsentiert. Bis vor kurzem ging man davon aus, dass die 
Hauptanwendung von hESC bei der Transplantation von Zellen, 
die aus hESC hergestellt würden, läge. Wir diskutieren hier, dass 
die wahrscheinlichsten Anwendungen eher im Bereich der in vitro 
Testsysteme und Krankheitsmodelle liegen werden. Größere und 
kleinere pharmazeutische Unternehmen sind auf dieses Gebiet 
eingestiegen, und die Europäische Union fördert akademische For-
schung an innovativen Testsystemen, die auf hESC beruhen. Diese 
Aktivitäten entsprechen Entwicklungen auf beiden Seiten des Atlan-
tiks, die darauf abzielen, mehr in vitro Testsysteme für die Evalu-
ierung von Sicherheitskriterien zu benutzen, die auf menschlichen 
Zellen aufbauen, und darauf hinzielen, den Fokus der Toxikologie 
weg von klassischen Tierexperimenten und hin zu einem mechanis-
tischen Verständnis zu richten.
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initiated, since the initially superfluous 
blastocysts are typically cryopreserved, 
i.e. stored in a liquid nitrogen tank where 
they can be maintained for several years. 
It is not known when a blastocyst under 
conditions of cryopreservation loses its 
potential to form an embryo. Albeit one 
case study reported a successful preg-
nancy after implantation of a blastocyst 
stored for 12 years (Revel et al., 2004), 
it is generally observed that the quality is 
strongly declining after 5-10 years. Many 
supernumerary blastocysts accumulate in 
fertility clinics and will be ultimately de-
stroyed. It is estimated that 400,000 ferti-
lized oocytes were stored in 450 fertility 
clinics in the USA alone in 2003. tens 
of thousands are also frozen in Germany, 
Switzerland, Austria, the UK and many 
european and Asian countries. thus, it is 
reasonable to assume that by now over 
one million pre-implantation embryos are 
stored in the USA and elsewhere. A very 
small minority of these (less than 1%) is 
typically donated for research purposes, 
including heSC generation (Fig. 1B).
the in vitro generation of heSC was 
first described in 1994 by Agriff Bongso 
(Bongso et al., 1994), and this break-
through was a direct result of his labora-
tory’s efforts to optimize the cell culture 
methods used in IVF. the procedure is 
depicted in Figure 1C, and it starts with 
thawing and propagating a superfluous 
donated day five pre-implantation blas-
tocyst. the ICM is isolated and placed 
in growth medium. these cells can be 
cultured in vitro, but they require a sup-
portive “feeder” cell layer to provide nu-
trients and hormonal signals. typically, 
mouse or human fibroblasts (connective 
tissue cells) are used as feeders. If the 
procedure is successful, the cellular out-
growth of this ICM will form the “pas-
sage 1” of a new heSC line, and once 
the cell culture dish is densely grown 
with heSC, the cells will be harvested 
and transferred to five fresh cell culture 
dishes. there they grow again to cover 
the whole dish (passage 2), and be trans-
ferred to new dishes, and this procedure 
can be repeated continuously to generate 
more cells (Fig. 2). It is now possible, in 
principle, to expand hESC indefinitely, 
and heSC have been cultured as stable 
cell lines up to passage numbers far be-
yond 150 using methods developed orig-
uterus. this process of “implantation” of 
the late blastocyst occurs around day 9 
post-fertilization and represents the first 
physical connection between the early 
embryo and the fertilized woman. this 
step, also termed “nidation”, is crucial 
for the development of embryo polar-
ity (body axes/up and down-definition). 
Finally, at day 12-14, a dramatic mor-
phological restructuring occurs when the 
embryonic cells form a double-layered 
structure – the gastrula. this is the start 
of primitive tissue formation (primitive 
streak) in the embryo proper (the real 
embryo). At day 14, therefore, pregnan-
cy is established, the embryo has a close 
connection to the womb, it has developed 
polarity as well as “inside” and “outside” 
directionality, and, importantly, the three 
germ layers (primordial tissues) begin to 
form early organs such as the primitive 
gut and neural system. In parallel the pla-
centa forms from formerly external cells 
of the blastocyst.
Couples facing problems in conceiving 
naturally (in some countries also women 
that can get anonymous sperm) now 
have the option to increase their chances 
of pregnancy by undergoing an in vitro 
fertilization (IVF) procedure. this proc-
ess differs from a naturally-occurring 
pregnancy only in the initiation phase 
where sperm and oocyte meet (Fig. 1B). 
Oocytes are harvested from the woman, 
and this process is facilitated by ovarian 
stimulation with hormones. then they 
are fertilized with a sperm sample from 
the potential father to form zygotes. typ-
ically, 10-15 early pre-implantation em-
bryos are generated in such a process and 
propagated in vitro up to the blastocyst 
stage (day 5). In some countries (e.g. 
Germany), national regulations forbid 
selection of the embryo after nuclear fu-
sion and preclude the cultivation of more 
than three embryos at a time (Zollner et 
al., 2003). After positive selection of the 
best blastocysts, 1-3 (depending on the 
country) are re-implanted directly into 
the uterus, where they have the chance 
to attach to the uterine wall and form 
an embryo just as it occurs in a natural 
conception. IVF procedures result in a 
successful pregnancy in about 15-25% 
of the procedures. If the first attempt is 
unsuccessful, a second and third round 
of re-implantation of blastocysts may be 
 1  Introduction and background
Human embryonic stem cells (heSC) are 
presently being cultured in many labo-
ratories, and differentiation protocols are 
available for a large variety of cell types. 
the most immediate use of these cells 
may not be therapeutic applications, but 
more immediately, the design of test sys-
tems for toxicological and pharmacolog-
ical research (UKtI, 2005; Bremer and 
Hartung, 2004; Vogel, 2005). the use of 
such human-based test systems would 
contribute to a bottom-up test strategy 
for new chemicals, where initially the 
mode of action is explored, and animal 
experiments are only used as a last re-
sort and in special situations (leist et al., 
2008a). One obstacle to the broad use 
of heSC for experimental test systems 
are ethical issues that have different le-
gal implications in different countries 
(MBBNet, 2008).
What are embryonic stem cells? 
Before entering a bioethical debate it is 
important to create a common platform 
of biological facts important for such a 
debate. We will first take a look at natu-
ral conception and embryo development 
as basis for the overall understanding 
of the technology (Fig. 1A). After fer-
tilization of the oocyte (“egg”) in the 
oviduct by a sperm, a zygote is formed. 
this cell, which contains genetic infor-
mation from two parental gametes (i.e. 
the oocyte and sperm) starts dividing 
while migrating down the oviduct, and 
gives rise to a tiny (less than 0.1 mm), 
blackberry-shaped, compact cell clump 
termed the morula, which eventually en-
ters the uterus at around day 4. By day 5, 
a cavity is formed in the “ball” and the 
resulting structure of embryonic cells is 
now termed early blastocyst. the blas-
tocyst is initially surrounded by a trans-
lucent structure (the zona pellucida) that 
protects it and prevents it from attaching 
to incorrect structures. In the uterus, the 
blastocyst begins to form different cell 
types – the outer cells (40-80), which 
will later become the placenta, and the 
inner cell mass (ICM) of about 20-45 
cells which will later develop the em-
bryo (Hardy et al., 1989). eventually it 
“hatches” i.e. it breaks out of the zona 
pellucida and attaches to the wall of the 
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What do hESC look like?... and how 
does typical work with hESC look like? 
…are questions that interest many peo-
ple involved in the debate. Often, there is 
also the question of how often embryos 
are required…, how many cells can be 
gained from an embryo… and how all the 
other cells are derived from heSC. Re-
search is often performed by specialists 
organism, because they are lacking the 
capacity for implantation and formation 
of a placenta. this capacity is only found 
in the zygote and the cells up to the 8-cell 
stage of the morula, and these cells are 
called “totipotent”. It is important to em-
phasize here that heSC themselves are 
not totipotent and they are therefore un-
able to generate a new embryo.
inally in 1998 in the laboratory of James 
thomson (thomson et al., 1998). heSC 
harbour the potential to form a diversity 
of different cells – theoretically any cell 
type of the about 200 existing in the hu-
man body. therefore, they are called 
“pluripotent” cells. Pluripotent means 
that the cells can form any known cell 
type, but they cannot generate a whole 
Fig. 1: Pregnancy, in vitro fertilization and the generation of hESC lines
The nomenclature for the developmental stages of the fertilized oocyte is shown for the first 14 days. (A) The different stages are  
shown in the context of natural pregnancy. (B) The different stages are shown in the context of in vitro fertilization (IVF).  
(C) The procedure for the generation of hESC is shown in the context of IVF. The time line is different from that in B and C.
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Fig. 2: The lifecycle of hESCs 
1) A research group isolates cells from the inner cell mass (ICM) of a human blastocyst.  
2) The cells proliferate in a culture dish and form colonies with cells lying closely together in a monolayer. 2a) When looking at the hESC at 
higher magnification, they resemble any other common cell type from the body (here compared to skin fibroblasts). The circumference of two 
individual cells is outlined with red in the cultures of hESC or fibroblasts, respectively, for better orientation  
3) The hESC proliferate and are expanded to yield millions of cells, which can then be frozen in small vials to be used for future experiments.  
4) Once the hESC are established, they are normally distributed to other research groups, where cells are further expanded and frozen. This 
expansion and freezing process can be repeated several times, ensuring that cells from one embryo can be used for many years in many 
laboratories.  
5) The cells that are not kept for storage or for further growth, are used for experiments  
6) To start an experiment, some of the hESC growing in the laboratory are placed in a new environment with growth factors that direct the 
differentiation of the cells. By choosing specific media, adhesion material and growth factors, the fate of the hESC can be controlled, i.e. the 
cells can be guided to develop into brain cells, muscle cells, or liver cells etc. The process of this “differentiation” can be studied in detail.  
7) Alternatively, the cells are kept in the dish with growth factors until they have matured into the specific cell type desired (i.e. dopaminergic 
neurons for Parkinson’s research or insulin-secreting cells for diabetes research). This can take up to 1-3 months.  
8) The mature cells are now ready to be used for experiments (shown here is a culture of brain cells with the nerve cells in red and the 
supporting brain cells (= glia) in green). These cells may be used for transplantation studies in animals (e.g. an animal model of Parkinson’s 
disease) or to test the efficacy or toxicity of new drugs on human cell types not available otherwise. 
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of laboratories worldwide; its usage has 
generated a tremendous amount of novel 
scientific knowledge which may enable 
future therapies, and it is still being used 
extensively today. Most laboratories 
working with heSC nowadays use such 
cell lines for their research, but were nev-
er involved in the generation of cell lines, 
i.e. the use of any blastocyst as explained 
in step 1 of Figure 2. So far, this is the 
sequence of events, but can we really 
identify a killer, a killing act, a weapon, 
and most importantly which person was 
killed, and whether indeed low motives 
were involved…? It appears that a more 
differentiated approach is required than 
the one seeing heSC only as evidence of 
a crime story. First, more biological in-
formation will be helpful. A closer look 
into the way information on the subject 
matter has been disseminated, may help 
to clarify the reasons for many misunder-
standings underlying the current heSC 
debate.
2.2  Issue 2: The definition of 
embryos and pregnancy
While some influential groups connote 
research on heSC as “embryo-consuming 
research”, others wonder about the origin 
of this statement, in view of the fact, that 
the large majority of researchers working 
with heSC have never in their life seen 
a human embryo, as they are merely us-
ing hESC for scientific research but have 
never generated a heSC line. this ap-
plies to researchers of many countries in 
the world (MBBNet, 2008). 
However, staying within the image of 
a crime investigation, one has to admit 
that knowingly profiting from someone 
else’s crime or basing one’s work on it 
would also be illicit and unethical. We 
have seen above (issue 1) that it is not 
clear, whether a crime is being commit-
ted at all in many heSC research applica-
tions. However, we still need to have a 
closer look at those labs where eSC lines 
are generated – and define exactly what 
they are generated from. We will deal 
later with the question whether the cell 
material used for heSC generation ever 
had the potential to become a human be-
ing. For now, we want to clarify the ques-
tion of whether heSC are at all generated 
from embryos in a colloquial sense? 
fertilized oocytes that had undergone 
about 7-8 divisions. the major objection 
to the use of eSC is that their generation 
is purported to involve an “act of killing”. 
In extreme cases, even the word “murder” 
is used (tab. 1) (Robertson, 2001). 
According to common definitions, the 
act of murder requires a killer, a person 
to be killed, a killing act, a weapon and – 
most importantly – low motives. In a clas-
sical detective story dealing with murder, 
the detective now needs to identify all 
of them, if they exist, and therefore we 
will scrutinize the current procedure of 
eSC generation for such details: First, 
the detective unravels the background 
story. A couple wishing to have chil-
dren decides to try in vitro fertilization 
(IVF) – oocytes are removed from the 
woman, fertilized with sperm, and two 
embryos are implanted into the woman 
as detailed above. the remaining em-
bryos are stored, frozen in liquid nitro-
gen, and the woman is lucky to become 
pregnant on the first attempt – possibly 
even giving birth to twins. life goes on 
and the couple is content with their two 
kids. After more than five years of stor-
age, the actual part of our detective story 
begins: Now, the quality of the stored 
blastocysts starts to deteriorate, and the 
storage is expensive as well. Presently, at 
least half a million such left-over zygotes 
are stored in the US alone. None of these 
blastocysts has any potential at all to ever 
develop to a human being without a fos-
ter mother. After parental consent of our 
happy couple, the leftover material will 
either be destroyed (moved to a trash 
can), or it may be donated for research 
purposes (only in some countries). em-
bryo adoption schemes as an alternative 
to discarding them were discussed and 
promoted by the pope, but this obviously 
does not appear to be a realistic option 
for all stored blastocysts at annual stor-
age costs of several hundred million $. In 
the case of research donation for heSC 
research, the blastocyst will be thawed, 
and heSC will be generated as explained 
above. When the procedure is success-
ful, this will result in the generation of 
a single continuously growing heSC 
line that can provide pluripotent cells in-
definitely. For instance the first such cell 
line, generated around 1998 (thomson et 
al., 1998) has now been spread to scores 
trained for many years and using a very 
particular vocabulary which can make 
explanations difficult. Also, the public 
often has no idea what is actually done 
behind the closed doors of cell biology 
laboratories. this is a problem in discus-
sions on the implications of this research 
that could easily be avoided. therefore, 
information is included here that allows 
any reader, even one without biological 
training, to quickly get a picture of typi-
cal work with heSC (Fig. 2).
2  Primary arguments:  
the status of IVF blastocysts
While ethics is classically a philosophi-
cal discipline it affects many other fields. 
In particular, bioethics and applied ethics 
deal with topics that are of strong pub-
lic interest. We believe that the discus-
sion should not only be left to the experts 
in religious and philosophical faculties 
but involve broad circles, including bi-
ologists (Mclaren, 2007). Opponents of 
this attitude sometimes claim that moral 
judgement does not require a complex 
ethical discussion, but a return to simple 
natural guidance principles. It is further 
claimed that … instead of ethical dis-
cussions, it is mainly the capacity to say 
no, in cases where those natural guid-
ance principles are in danger of being 
violated... Whatever approach one con-
siders right, it will always be so that we 
can only judge on things as we see and 
comprehend them. A correct judgment 
therefore requires that we have a view of 
the facts that is as clear and as complete 
as possible, that information is true and 
valid, and that we understand the con-
nections between the main components 
of the picture and the consequences of 
changes. For this reason, a picture of 
the ethical and biological background of 
the stem cell debate is compiled here in 
one review, bringing together biological 
background knowledge and other impor-
tant non-biological issues.
2.1  Issue 1: The question of 
killing
the use of heSC in research requires the 
generation of heSC lines. the lines cur-
rently used were mostly produced from 
Leist et aL.
Altex 25, 3/08168
nate exactly when a pregnancy starts: at 
implantation of the blastocyst – not be-
fore. this is precisely why measures that 
prevent nidation and therefore the estab-
lishment of pregnancy after fertilization 
are medically as well as legally, consid-
ered “contraceptives”. examples would 
be the intrauterine device (IU) which is a 
widely used contraceptive (currently 160 
million woman according to the WHO), 
inner organs, such as the heart, are devel-
oped and the brain is forming. In medi-
cal terms, only the very early stages of 
development, before the fetal stage, are 
called embryonic stages. 
Why are such definitions important? 
Doctors, lawyers and policy makers need 
to know what they are talking about, and 
hence in these two disciplines clear defi-
nitions have been agreed upon to desig-
From the abortion debate, there exists 
quite a clear concept of what an “em-
bryo” looks like: Beating heart, facial 
structures, clearly-discernible arms and 
legs – and a size-dimension visible to 
the human eye or by ultrasound imaging 
devices. Such an “embryo” is called a 
“fetus” in medical terms. the fetal stage 
of development extends from the 9th 
week after fertilization until birth. the 
Tab. 1: Overview over ethical issues 
The numbering refers to the numbering of the chapters in this review. The major arguments for and against the use of hESC are shown in 
green. Issues that describe the debate on hESC itself and give background information are highlighted in yellow. Alternatives are shown 
in beige.
Issues: Arguments referring to the use of embryonic stem cells in research
 Supportive: Rejecting:
1. Killing No killing; continuity of cell line  Destruction of embryos
2. Embryo consumption Use of waste material, not embryos Use of human embryos
3. Human personhood Gradual acquisition over 1-2 weeks Full status at zygote formation
4. Basis for personhood Nidation and maternal signals required Continuity, Potentiality, Identity
5. Simple rules Not applicable to biological complexity New chromosome set defines life
6. Alternative start Brain (nerves) defines full personhood Brain is only qualitative step
7. Significance of nidation Go – no go decision One of many steps only
8. Balance of values Yes – differentiated views No compromise or balancing
9. Protection of life hESC research perpetuates life of surplus IVF embryos hESC is based on embryo use
10. Protection of the weak Nothing to protect in a nitrogen tank Obligation to protect unborn life
11. Human dignity Only partially assigned to blastocysts Unconditional and absolute
12. Therapy as balance Fundamental duty to heal, if possible hESC not acceptable
13. Prevention of damage High benefit to mankind hESC not acceptable
14. Toxicity testing High benefit to mankind and animals hESC not acceptable
15. Basic science Freedom of science: fundamental right hESC not acceptable
16. Cultural aspects hESC acceptable to many religions Pope: absolutely non-acceptable
17. Slippery slope Don’t stop all progress on principle Beware of first step
18. Rhetorics, use of “pro-embryos” hESC “generation” “Embryo-consuming”; “murder”
19a. Manipulation Hopes for immediate therapy Truisms and pseudologics
19b. Logical argument Problem: Emotional arguments, often given logical or scientific appearance
20. Ethical standpoint Interplay of science and ethics Absolute standpoint
21. Claim of authority Scientific insight into complex issues Defense of moral and values
22. Irrational fears Confidence requires time and transparency; control helps to build trust
23. Opinion formation Learning process. Ethical re-evaluation Ethics unchangeable
24. Practical responsibility Care about consequences of hESC ban Indifferent to consequences
25. Inconsistencies Resolve by allowing hESC research Resolve by banning abortion
26. Intellectual property Patents do not restrict hESC research No patents on life
27. Commercial aspects Patenting of methods drives therapy No commercialization of humans
28. Secondary interests Must be separated from the real ethical debate and often confuse the public
29. New cell lines Required for high quality applications Old cells must suffice
30. Adult stem cells Have serious practical limitations To be considered as alternative
31. hESC plus embryo  Preimplantation diagnostic: hESC generation without preventing pregnancy
32. Promises of iPS cells Do we understand them enough? How do we deal with new ethical issues?
33. Nuclear transfer Immuno-matched ESC; basic science No oocyte use; instabilities
34. Disabled embryos Discarded embryos as realistic source? Oocyte modification as dead end
35. Issues of the future Generation of gametes from hESC/iPS and in vitro interbreeding; parenthood and embryo definitions  
 of “somatically-derived zygotes”; nuclear transfer
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towards the first version, whereas most 
Jewish and Muslim communities favor 
the second version. Countries with strong 
protestant churches have largely varying 
attitudes. For instance, the last version is 
officially supported in the UK or Sweden. 
there, the embryo has some initial moral 
status because of its human origin and its 
theoretical potential of becoming a per-
son. therefore clear limitations and strin-
gent controls exist for embryo-related 
research, such as the justification of re-
search by other values and realistic goals, 
required approval from an established 
ethics board, and the use of embryos only 
from certain sources. the status increases 
over the first 2 weeks of development to 
reach full assignment of personhood af-
ter 14 days and thus the full status of hu-
man dignity and its protection. Similarly, 
more liberal regulatory frameworks were 
adopted by other countries, namely Sin-
gapore, Australia, and Israel, whereas the 
USA adopted a more restrictive approach 
(MBBNet, 2008). 
man rights and therefore does not de-
serve the specific ethical consideration 
of a person (Schuklenk, 2008). 
• In between these extremes, there are al-
so views that acknowledge the zygote as 
being unique (as opposed to other cells) 
in its natural, but theoretical, potential-
ity to become a human being, but that 
full human personhood and the rights 
associated with it are acquired gradu-
ally. Here, metaphors are often evoked 
of the embryo being a walnut, a cherry 
or a caterpillar, which may or may not 
become a walnut tree, a cherry tree or a 
butterfly – but they certainly are none 
of the latter, and therefore they deserve 
a different status. No one would, for in-
stance, argue that each walnut deserves 
the same protection as a full-grown 
walnut tree.
these views greatly differ according 
to country and culture. For instance, the 
Catholic Church, and countries with a 
strong Catholic influence on politics tend 
or emergency contraceptive pills given up 
to 72 h after a suspected conception, such 
as the progestin levonorgestrel (Wellbery, 
2000). In contrast, pregnancy interruption 
(abortion) can by definition only happen 
after pregnancy has been established, not 
before. Accordingly, the embryo defini-
tion of the American encyclopedia of 
medicine starts with implantation (ex-
cluding the stages prior to it). As shown 
in Figure 1, implantation of the blastocyst 
occurs at around day 7 after formation of 
the zygote and heSC lines are generated 
from a developmental stage that occurs 
before implantation, i.e. in strict medi-
cal terms from pre-embryonic stages. 
Sometimes the terms “pro-embryo” or 
more exactly “pre-implantation embryo” 
is used for exact distinction of this stage. 
However, the term “embryo” may also be 
used generically to comprise all stages of 
development starting from the oocyte. It 
is just important to be aware of what is 
really meant. Knowledge of these precise 
facts should be prerequisite for opinion 
formation on whether embryos are in-
deed consumed for heSC generation. 
Whatever the result of this considera-
tion, one has to be aware of the fact that 
the microscopic pre-implantation mass 
of less than 200 cells serving for heSC 
generation is not what the general public 
imagines in the word “embryo” (Fig. 2). 
Further intricacies of the embryo defini-
tion are discussed under issue 35.
2.3  Issue 3: Beginning of human 
personhood
It may be argued that size, morphology or 
exact medical terminology of an early hu-
man being do not really matter, if indeed 
a person is killed. Agreeing with this pre-
sumption, the definition of “human per-
sonhood” is the most crucial issue, and a 
wide range of viewpoints exists (Fig. 3):
• On one side of the spectrum one can 
find views that human life and person-
hood begin and reach their full extent 
within a single moment, when the nu-
clei and chromosomes of the gametes 
combine (day 1 in Fig. 1). 
• On the other side of the spectrum one 
finds views that the first days after the 
zygote formation merely result in the 
formation of a “pile of cells” (morula/
blastocyst stage, up to day 10 in Fig. 1) 
which cannot yet be assigned full hu-
Fig. 3: Different models to explain the beginning of personhood and the assignment 
of human dignity
Initially the gametes fuse to a zygote. This time point is arbitrarily set to zero on the time 
scale. Note that the state of the human dignity is larger than zero also for the gametes. 
They are donated human tissue with a particular status. The black line describes the 
view of the world of different churches (e.g. the Catholic Church). The blue line stands 
for different views, that assume that the zygote does not have the full personhood status, 
and that this status is reached over time in parallel with certain biological steps (nidation, 
development of tissues, development of the nervous system …). The red line stands for 
models based on one defined event, day (e.g. by legal definition) or biological process in 
the development of the embryo, which leads to full assignment of human personhood.
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time (i.e. over several cell divisions) to 
give way to the information now en-
coded by the new mixed genome. thus, 
the time point of nuclear fusion is not so 
unambiguously clear, as it may appear 
at first glance. It is one of many poten-
tial time points to define the beginning 
of personhood, initially chosen for clar-
ity and simplicity. In addition, we have 
learned that our personality is not only 
a product of our genes. Now, in the age 
of epigenetics – which means influence 
of the environment on gene expression 
– additional factors are being discov-
ered every day. When the time point of 
ensoulment was chosen, there were no 
major practical implications, whether it 
was this time point or some days later. 
Now, the choice of this time point is at 
the basis of an ethical dilemma for many 
people. this does not only involve heSC 
research. For instance, the definition of 
life by the Catholic Church means that 
a lot of life is created that can never re-
ceive the holy sacraments of this church 
(as a large proportion of pre-implantation 
embryos dies unnoticed before nidation), 
and it also means that IVF embryos not 
used further would require a formal fu-
neral. therefore, it appears fair to ask the 
question, whether such an important time 
point should be chosen and maintained 
just because of its apparent simplicity at 
times when it was defined, or whether it 
should not undergo (biological) re-evalu-
ation – as it occurred many times before 
in history.
On the side of supporters of heSC re-
search, there are also attempts to reduce 
the ethical problem to a single issue that 
can then be addressed easily. At the ba-
sis of their consideration is the claim that 
‘a woman from whose oocyte an embryo 
is formed in vitro is (together with the 
co-progenitor) the only person in the 
world privileged to decide whether the 
embryo will be transferred to the uterus’ 
(Guenin, 2005). It is purported that no 
moral obligation can exist for the woman 
to undergo the transfer of the embryo or 
to allow adoption of the embryo by a fos-
ter mother. thus, if the woman actively 
decides against intrauterine transfer, 
and gives informed consent for dona-
tion of the embryo for research, then it 
must be regarded as belonging to a “spe-
cial set of embryos”. This set is defined 
tus. Following this argument we would 
indeed be ethically on safe grounds to as-
sign some human status to a zygote, but 
the question on whether personhood and 
human dignity are acquired in one step 
or gradually would then still remain un-
resolved.
A different line of argument addresses 
the time point of the acquisition of per-
sonhood more directly. It takes its origin 
from the utilitarian school of bioeth-
ics and asks whether the embryo has an 
interest in itself or its fate. Personhood 
is strictly associated with a concept of 
individual interest, at least in its most 
primitive and basic sense (e.g. pain, hun-
ger with reference to a self). It is then 
concluded that, as the blastocyst has no 
nerve cells at all, it cannot have even the 
most primitive form of an interest and 
therefore it cannot be assigned full per-
sonhood (Singer, 1979).
2.5  Issue 5: Simple is beautiful – 
or not?
the arguments above appear intricate as 
the Gordian knot. One feels tempted to 
solve the problem with a single cut, like 
Alexander the Great. this solution is for 
instance offered by the Catholic Church, 
which declares that the soul enters the 
zygote at the exact moment of nuclear 
fusion during fertilization (day 1 in Fig. 
1). As ensoulment is associated with full 
personhood, this provides evidently a 
clear definition of status and time point. 
To some extent the theological defini-
tion of personhood is also supported by 
biological concepts. this new combina-
tion is at the basis of a new creation, of 
something never having existed before 
and having a unique identity (unless we 
look at the two exceptions – when twins 
are formed from one zygote, or when fu-
sion of two zygotes leads to one embryo). 
the genetic composition makes the ma-
jor difference in the construction plan of 
parents and children.
However, living beings are not only 
construction plans, but actually real con-
structions. On this level, the situation is 
less clear. For instance, we know nowa-
days that the zygote is naturally very rich 
in maternal genetic and non-genetic in-
formation, which is initially absolutely 
dominant and is diluted out only over 
2.4  Issue 4: Personhood of the 
embryo
We have no authority of deciding who is 
right in the above issue (issue 3), but we 
can look at the basic concepts associated 
with these different views. 
One line of thought builds on the con-
cepts of continuity, identity and potenti-
ality. Obviously, a zygote does not fit our 
intuitive and accustomed picture of a hu-
man being. Still, it clearly belongs to the 
human race (biologically). In order to as-
sign the status of personhood to a micro-
scopic pile of cells, is has to pass at least 
the test of the following characteristics: 
• A defined succession of events leading 
invariably from the zygote to a human 
person (= continuity); 
• A situation in which one zygote only 
becomes one person and one person 
can only be derived from one single zy-
gote (= identity); 
• The full capacity of a zygote to become 
a human person without further ma-
nipulation or help (= potentiality). 
If one accepts that these three require-
ments are met, and if one assumes that 
fulfillment of these requirements is both 
necessary and sufficient for the person-
hood definition, then a zygote indeed is a 
human being. 
However, biological research in mam-
mals has shown that these assumptions 
may not hold true: the continuity crite-
rion is not fulfilled, because most zygotes 
(∼70%) never become persons (because 
of implantation failure), the identity cri-
terion is not met, because one zygote can 
produce twins, and vice versa some per-
sons are made up from two fused zygotes, 
and the full potentiality is not found in the 
zygote, as an embryo can never develop 
to a person in the absence of the mother’s 
womb, i.e. without maternal signals re-
ceived upon implantation. It may also be 
argued that these requirements are neces-
sary, but not sufficient (see issue 3, grad-
ual acquisition of personhood).
these are indeed serious biological 
objections to the personhood status of 
the zygote. In defense of this status, it is 
sometimes argued that we can indeed not 
be sure whether a zygote (or a blastocyst) 
fulfills the criteria for personhood, but 
if there was only a slight chance that it 
may be so, we need to assign it this sta-
Leist et aL.
Altex 25, 3/08 171
words, if we agree that a person who 
has lived and left traces in the world 
by the interaction with other people, by 
friendships and by family relation, is no 
longer alive when brain activity is gone, 
then how can we claim that an embryo 
which has never had any form of neuro-
nal activity or personal interaction is a 
living person? 
2.7  Issue 7: Nidation as 
qualitative or quantitative step
For some, it would be hard to accept that 
the definition of personhood could be 
linked to the development of the nerv-
ous system. Such a definition may look 
biologically fuzzy. therefore, another at-
tempt to define a rational and clear time 
point for the start of personhood focuses 
on nidation (=implantation). As discussed 
above (issue 2) and illustrated in Figure 1, 
this biological step forms the basis for the 
medical and legal definition of the start 
of pregnancy. As pregnancy can only be 
interrupted after it has started, abortion 
can legally and medically only apply to 
procedures initiated after nidation. this 
situation suggests a different status of the 
embryo before and after nidation. Such a 
view would at least be legally consistent. 
But again, there are different viewpoints. 
these depend largely on whether nida-
tion is seen as a qualitative or quantita-
tive step, i.e. whether one assumes that 
a new quality of human development is 
reached after nidation or whether one 
just sees this as one of many steps in the 
continuous development of the zygote to 
a fetus. 
• Supporters of the qualitative nature of 
nidation claim that continuity and full 
potentiality are only reached after im-
plantation of the blastocyst, as many 
blastocysts are lost before implanta-
tion, and there is a strong maternal 
influence that constitutes an essential 
developmental step. A variant of this 
view is that nidation is one of a series of 
qualitative steps. It may either be seen 
as the last decisive step after which full 
personhood can be assigned – or as es-
sential prerequisite for gastrulation and 
primitive streak formation after which 
full personhood can be assigned.
• Supporters of the quantitative step claim 
that zygote formation already results in 
makes up a person as opposed to a human 
body? It is the capacity to think, to feel, 
to have awareness, including self-aware-
ness and the capacity to have ideas, inter-
ests and emotions. None of these would 
be possible without a brain. therefore the 
legal definition of death is based on the 
absence of brain activity, even though all 
the rest of the body is viable. Indeed, a 
living body without a brain would be a 
mass of cells without personhood. Nota-
bly, it would still be endowed with a cer-
tain degree of dignity. 
The example of the definition of death 
has implications for the personhood defi-
nition on the other end of human life: 
• First, we can learn here that a mass of 
cells is not necessarily only a mass of 
cells. the above case gives a good ex-
ample that this would be an oversimpli-
fication that nobody intends. In all cul-
tures, the human body (mass of cells) 
is not just a “thing”, and it requires due 
respect, even though it does not have 
the same rights and status as a human 
person. Similarly, research with any hu-
man tissue, be it a medical specimen, a 
transplanted organ or a cultured cancer 
cell line, is under some degree of regula-
tion and ethical oversight. Why should 
this approach not be applicable to very 
early human developmental stages as 
well? 
• Second, the absence of neural activity 
means that typical characteristics of per-
sonhood cannot be present. In extreme 
cases of brain death (erlangen baby) 
the body can still function for weeks 
and even support pregnancy, although it 
does not have a personhood anymore. In 
this case we have accepted that the hu-
man body without a functioning brain 
is not regarded as a live person. We do 
not know when the embryonic nervous 
system starts functioning, but we know 
that it cannot function before it is de-
veloped, and we know when it starts 
developing. Before that time point, 
we would deal with human tissue, re-
quiring respect, but not possessing the 
status of full personhood. If we look at 
time points where tissue development 
has not even started (before implanta-
tion and gastrulation of the blastocyst at 
day 7-10, see Fig. 1) – would it not be 
reasonable to see this as being a sym-
metrical case to brain death? Or in other 
as, being barred from the womb. By all 
logics, such embryos have no potential 
to develop into a human being. No pos-
sible person would correspond to such 
an embryo. thus, it could be considered 
and used under the regulatory guidelines 
of the transplantation law. this approach 
would solve many ethical issues, but 
there does not seem to exist basic agree-
ment on the initial assumptions. In many 
countries it is not accepted that responsi-
bility for the fate of the embryo lies only 
with the oocyte donor, and even the right 
of a woman to refuse implantation is con-
tested in some countries such as Italy. It 
is also unclear how, in this situation, pro-
duction of embryos for research would 
be distinguished from left-over embryo 
use. thus, the approach can be helpful, 
but it is possibly oversimplified. It is in 
most cultures not the ultimate and simple 
solution to the problems of heSC use.
2.6  Issue 6: Symmetry of life 
and death
How do we arrive at a rational, clear and 
generally acceptable definition of the be-
ginning of personhood, which can substi-
tute one based mostly on the wish to keep 
it simple? A related problem arose when 
the time point of death needed to be de-
fined. For instance, after a motor cycle ac-
cident and severe head trauma, the brain 
can stop working while the heart (if sup-
ported) may go on beating and supplying 
the organisms with oxygen and nutrients 
for days and weeks. Organs thus remain 
viable and usable e.g. for transplantation. 
Once the heart stops beating, individual 
cells can still remain viable for many 
hours or days, and be isolated for tissue 
cultures. the DNA, earlier supposed to 
be the determinant of personality, can 
remain stable for many years (e.g. when 
the body is rapidly frozen). thus, death 
occurs at many levels, and – most impor-
tantly – in a gradual fashion. A simple, 
easily intuitive and historically validated 
definition may be the stop of heart beat 
for a certain time. However, what hap-
pens, when a heart is transplanted or a 
cooled body is reanimated? ethical di-
lemmas arose due to a technological in-
novation. 
To define death, one could alternative-
ly ask, when does personhood end? What 
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heSC generation would result in a pro-
tection of life. A particularly important 
aspect of the discussion on protection of 
life is the claim that this must be uncon-
ditional, and that lives cannot be balanced 
against one another. these are arguments 
that need to be taken seriously, but these 
arguments also require great care and re-
sponsibility when they are used. 
the imperative of the protection of hu-
man life is universally accepted, but also 
repeated without reflection like a mantra. 
therefore, one wonders what is really 
meant – or indirectly implied – when this 
is mentioned. Often the argument is not 
as innocent and pure as it appears, but it 
is used as an accusation that someone is 
not willing to protect human life. In the 
context of heSC, the use of this argument 
implies that heSC research destroys life 
instead of studying life, maintaining life 
and preventing harm to life. In countries 
(such as Italy, Germany) where no heSC 
cell lines are generated, researchers can 
get permission to work with certain pre-
existing cell lines. the research they car-
ry out (covering the entire activity of sev-
eral large countries) does not sacrifice a 
single life, directly or indirectly. Whether 
this research is performed or not – it has 
no effect on the previous generation of 
these cell lines. the cell lines have ex-
isted for several years, and their present 
use does not lead to the use of a single ad-
ditional embryo. Unaware of this, a lot of 
people have been misled by the apparent 
argument of “protection of life”. 
the situation presents itself different in 
countries where heSC may be generated. 
Under certain assumptions, one may build 
a case for the protection of the life of the 
blastocysts used for the generation of the 
cell lines (see discussion above on issues 
concerning the beginning of life and per-
sonhood). this argument would be valid 
and consistent under the assumption that 
full human personhood begins at fertiliza-
tion of the oocyte. However, it remains a 
theoretical argument that does not live up 
to the practical reality. the decision on the 
fate of a fertilized egg is not taken by the 
researcher trying to derive heSC cells. the 
decision has been taken long before by the 
parents and IVF doctors involved. they 
have decided against an implantation of 
the embryo into the woman. Without im-
plantation, the “embryo” has no continuity 
100 other frozen zygotes (embryos). One 
year later, the wife has an early morn-
ing appointment at the IVF clinics for a 
hormonal check for future planning. the 
doctor is in a wheelchair. Neither one of 
them initially notices the fire starting that 
prevents them from taking the elevator. 
the wife now has the choice of either 
saving the doctor by assisting him down 
the stairs and out of the house, or moving 
the 100 embryos (including her own two) 
in the big cryo-container. What would be 
her most likely choice in a real world?
3  Secondary arguments: 
balance of values
If one agrees, that the zygote has some 
type of special moral status, be it partial 
or complete personhood, then it cannot be 
used without certain restrictions. this sit-
uation is not specific for hESC research, 
but applies generally to the use of human 
material and in particular for transplanta-
tion. The field of organ donation and use 
of tissue for medical purposes has had a 
long time to deal with ethical issues and 
mature viewpoints have been developed 
and transformed into guidelines and leg-
islation. One of the underlying principles 
is that the use of human material is ac-
ceptable, but needs to be justified by a 
real or envisaged benefit of another hu-
man being or by the progress of science 
which serves a greater good. In some 
countries the practicability-tested ethi-
cal framework developed for transplan-
tations has been adopted for the use of 
pre-implantation embryos. this applies 
to the rules pertaining to the source of 
the material, to the informed consent and 
to the guidelines for the potential use of 
the pre-implantation embryos. Whatever 
country or culture, a reasonable balance 
of values must be evident in order to use 
human material, including heSC.
3.1  Issue 9: Protection of life
Arguments supporting a use of heSC in 
cases when the value balance appears 
correct (see issues 12-15), are frequently 
wiped aside by the claim that protection 
of life supersedes all other values. this 
line of thought further implies that giv-
ing up of heSC research and banning of 
full potential, as the effect of the implan-
tation is minor or may be bypassed when 
more technical and biological knowledge 
becomes available. Also, that maternal 
signals and a differentiation axis are 
already present before nidation, but are 
possibly not detectable by present tech-
nology. Moreover, some claim that the 
loss of most of developing zygotes (up 
to 70%) before nidation would not mean 
that the basic principle of continuity is 
not fulfilled, as death can, for instance, 
happen also to babies after birth without 
their personhood being questioned. For 
an elaboration of the latter point see also 
issue 19 (different logics).
2.8  Issue 8: Choices of reality
It appears hard to find scientific argu-
ments for one or the other position that 
could not be disputed to some degree. 
Many other dimensions of argumentation 
have therefore been explored: legal, re-
ligious, medical, philosophical, and oth-
ers. Although this theoretical exercise is a 
highly important process for society, one 
should not neglect to make a reality check 
from time to time to see whether theory 
is still coupled to reality. let’s look at 
some imaginary stories: For instance, 
let’s assume that eSC-based therapy has 
been developed in your neighbor country 
(e.g. France or the UK) and is used suc-
cessfully and safely e.g. for Parkinson’s 
disease. the therapy itself may not im-
ply the use of eSC at all. Your spouse 
or a parent get the disease. Would you 
seek this therapy, if it was available in 
your own country? Would you seek this 
therapy in your neighbor country? If that 
therapy was forbidden in your own coun-
try, should your spouse/family seeking it 
abroad be held morally guilty of killing 
embryos? Or would you prefer to let oth-
ers deal with problems of heSC research 
and then benefit in the end? Another re-
ality check often mentioned in the stem 
cell debate is more extreme, but still use-
ful as food for thought: A young couple 
has undergone an IVF procedure. three 
good oocytes were successfully ferti-
lized. One was implanted and resulted 
in a baby (e.g. one of the 1-2% children 
born e.g. in Germany from IVF). two 
were frozen. they are stored in a cryo-
container in liquid nitrogen together with 
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or price setting, and thus it prevents value 
balances as discussed above. the life of 
one person cannot be balanced by any oth-
er value, including the lives of other per-
sons. the fundamental nature of this posi-
tion is important for the understanding of 
the debate on the use of human embryos. 
Viewpoints on the fundamental question 
of human dignity cannot be relative (bal-
anced) in many legislations. An example 
from the German legislation exemplifies 
how high this principle is held: §14 of the 
“Luftsicherheitsgesetz” (a law concerned 
with air traffic) would have allowed that a 
plane, hijacked by terrorists and directed 
towards a huge sports arena to kill tens of 
thousands of people could have been shot 
down. this law was declared unconsti-
tutional, because it would lead to volun-
tary killing of the hostages, even if these 
would only have survived 5 more minutes 
until the crash. In simple mathematical 
terms; human life is assigned an endless 
value, and then 100,000 times endless 
(the lives of spectators in the arena) is not 
more valuable than 5 or 50 times endless 
(the lives of the hostages). If we want to 
be true to our constitutions and their cur-
rent interpretation, then we cannot justify 
embryo research by a balance of human 
lives against other benefits. However, we 
can ask when in life personhood begins, at 
what rate it grows and when it has reached 
the level when full human dignity applies. 
If one assumes partial personhood up to 
the blastocyst stage, the balance of values 
becomes important. If full human dignity 
applies from the moment of fertilization 
as proposed by the Catholic Church, 
then indeed a consequent standpoint is 
the rejection of heSC research. Alterna-
tive views to the extremely unconditional 
view of human dignity are discussed un-
der issue 24.
3.4  Issue 12: Therapeutic 
applicability
the value most frequently discussed in 
the context of heSC is their therapeutic 
applicability. this argument has been 
promoted so violently, that it is often per-
ceived as the only argument favoring the 
use of human blastocysts for research. 
the vision of healing diseases ranging 
from cancer and neurodegeneration to 
diabetes and stroke is appealing and the 
asked or could not express their intentions 
whether they wanted this protection. 
Similarly, we also do not know wheth-
er surplus IVF blastocysts desire this 
protection. We do not know whether they 
“prefer” to be disposed of or have their 
existence prolonged 180 degrees in a ni-
trogen tank, over the transformation into 
an heSC cell line. However, we know 
one thing for sure, that wanting, having 
interests and intentions, are hard to imag-
ine without any form of nervous system, 
and blastocysts do not contain a single 
nerve cell. It is therefore entirely unclear 
what actually “protection of the weak” 
means in this context. even if we would 
assign full personhood to blastocysts, 
what would be the best fate for them if 
we seriously want to “protect” them? 
theatrically-speaking: “eternal impris-
onment in liquid nitrogen”, “growth in a 
cell culture dish” or “rapid death in a trash 
can”? Hence, we need to find some clar-
ity, before we can seriously consider the 
argument of “protection of the weak”.
3.3  Issue 11: Inviolability of 
human dignity
Within the triad of fundamental moral 
arguments, protection of human dignity 
complements protection of life and pro-
tection of the weak. Again, the argument 
appeals at an emotional level, and it builds 
on a recognition effect. We all know the 
principle of the inviolability of human 
dignity as fundamental right from con-
stitutions, declarations and human rights 
charters. the imperative is self-evident 
and learned from early childhood. It is the 
highest principle of most Western consti-
tutions, but it is also astonishingly difficult 
for many to define exactly what is meant 
by human dignity. It signifies that all hu-
man beings possess inherent worth and 
deserve unconditional respect, regardless 
of factors such as age, sex, abilities, so-
cial status and intelligence. this respect is 
owed to every individual by the mere fact 
that he or she is a “member of the human 
family” (Universal Declaration of Hu-
man Rights, 1948, Preamble). In practical 
terms, human rights derive from this in-
herent human dignity. Another important 
aspect for the heSC cell debate is that 
dignity makes every person irreplaceable. 
It prevents instrumentalisation of a person 
and potentiality and thus also in all possi-
ble views and interpretations no chance of 
ever becoming a human person. 
At this stage the blastocyst is called 
a surplus IVF embryo, and only at this 
stage, when the decision on life (or not) 
has already been taken, can a scientist 
consider the material for use of cell line 
preparation. It is important to note that 
surplus frozen embryos from IVF repre-
sent in practice an almost unlimited source 
for the generation of heSCs. therefore 
life is not generated through fertilization 
of oocytes with the sole purpose to “de-
stroy” them to obtain a source of heSCs. 
With the use of these embryos, life is not 
extinguished, as would happen when the 
surplus IVF embryos are discarded, but 
the biological life is even maintained 
and perpetuated. In view of this situa-
tion, objections to heSC research due to 
the argument of the “protection of life” 
appear somewhat hypocritical.
3.2  Issue 10: Protection  
of the weak
An important argument sometimes used 
against heSC research is our obligation 
to protect the weak. like the protection 
of life discussed above, this has a strong 
emotional aspect and easily generates 
consensus. Protection of the weak often 
means protection of a weak individual, 
even at the immediate disadvantage of oth-
ers or the larger community. this concept 
of “reciprocal altruism” is a highly impor-
tant part of human culture, even though it 
is not only out of ethical reasons, but also 
driven by the fundamental underlying 
psychology that we would like to make 
sure that others would help us, if we be-
come weak. thus, probably all sides agree 
on a duty to help the weak. However, the 
use of this argument in the heSC debate 
requires great care and responsibility, as 
it easily diverges attention from the real 
issues and because this argument has the 
potential to be misused. For instance, this 
argument has been used when a group of 
professional revolutionaries took over the 
Russian empire in 1917. It was used to 
prevent women from gaining full equal 
rights, colonies from gaining independ-
ence, and slaves from gaining their free-
dom. One common issue in all these cases 
is that the “protected” ones had not been 
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• Indirect development of therapy: heSC 
have more therapeutic potential than 
just transplantation. Research on heSC 
is important to gain understanding about 
endogenous tissue-forming and regen-
erative potential. this will form a basis 
for future therapies stimulating endog-
enous repair mechanisms or preventing 
degeneration due to defective differen-
tiation. A broad understanding of heSC 
differentiation pathways will also be an 
important step toward the generation 
of new tissues from other cell sources. 
these may not be available yet in sig-
nificant quantities (e.g. brain precursor 
cells), but may be generated later with 
help of knowledge gained from heSC 
research (Guan et al., 1999). heSC-
based systems may also significantly 
aid the production of vaccines and 
other biological therapeutics. Finally, 
the fields of stem cell research and gene 
therapy may synergize some day by us-
ing stem and precursor cells as vectors 
for a successful gene delivery. Knowl-
edge gained from heSC cells will most 
likely be very valuable here.
• Help for development of classical 
therapy: Another therapeutic benefit of 
heSC, which may be realized relatively 
soon, is the application of heSC-based 
test systems for the faster and better de-
velopment of classical drugs (SC4SM, 
2008; Schrattenholz and Klemm, 2007; 
Klemm and Schrattenholz, 2004). Ma-
jor pharmaceutical companies like 
Novartis, GSK and Pfizer have only re-
cently started to involve themselves in 
heSC technology by forming a consor-
tium that funds heSC research (SC4-
SM, 2008). Also biotech companies 
such as eSI, that had a strong focus on 
cell therapy, are now shifting attention 
towards test systems (Baker, 2007), and 
the leading european companies such 
as Stem Cell Sciences and Cellartis 
have for many years worked according 
to a business model directed towards 
test systems. Similar to animal models 
in the past, heSC-based systems may 
provide new insights into human dis-
ease pathways and facilitate discovery 
of new drug targets (luttun and Verfail-
lie, 2006; Strübing et al., 1995; Wobus 
and Hescheler, 1992). likewise, in drug 
discovery programs, efficacy and safety 
of drug candidates may be optimized on 
• Transplantation: the primary applica-
tion dominating public discussion is the 
generation of tissue from heSC cells 
for purposes of transplantation to re-
place deficient tissue in a patient (“cell 
therapy”). One may for instance gener-
ate precursors of dopaminergic neurons 
and use them to substitute the loss of 
such cells in Parkinson’s disease, or 
one may generate insulin-producing 
cells and transplant them into diabetic 
patients. In other cases bone, or con-
nective tissue, or skin may be produced 
to help patients after burn injury and 
trauma. It appears at the moment in the 
field of regenerative medicine that there 
are many diseases and conditions that 
cannot be healed by drugs, and where 
cell therapy may be an additional op-
tion. Further into the future, perhaps 
infarcted brain or heart tissue may be 
repaired. the present therapeutic prom-
ise of heSC research is comparable to 
the status of gene therapy 10-15 years 
ago. We have to admit that gene therapy 
has not yet fulfilled much of its prom-
ises. It is also clear already now, that not 
all diseases will be cured by transplan-
tations. even in diseases with a good 
rationale for transplant therapy, such as 
Parkinson’s disease (Björklund et al., 
2003; li et al., 2008), the success and 
scope of classical transplantation has 
until now been relatively limited. It also 
has to be considered that the problem 
of tissue rejection has not been solved 
for heSC-based transplants. Very ba-
sic problems, such as the production of 
sufficiently high cell numbers and pure 
cell populations to test the therapeutic 
use, have not yet been overcome, not 
even for a single therapeutic indication. 
Notably, the first potential clinical trial 
initiated by Geron that intended to use 
heSC-derived material has been put on 
hold by the FDA just recently (Baker, 
2008). Although there may be a great 
potential to heal certain diseases by tis-
sue replacement therapy with heSC, 
this potential may be far less than some-
times stated in political debates, and it 
will probably take another 10-20 years 
before we will have a good guess which 
ones they will be. However, the use of 
stem cells for trophic effects and immu-
nomodulatory therapy may yield thera-
pies sooner.
strong enthusiasm based on this vision 
may have contributed to some blurring 
of the borderline of science and science 
fiction. To some extent the argument of 
therapeutic use was utilized to exert mor-
al pressure on those objecting to heSC 
research, and furthermore the sparkling 
vision of new heSC-based therapies was 
(and is) vividly promoted by small Bio-
tech companies that were (and still are) in 
need of raising funding in a difficult en-
vironment with most big pharmaceutical 
companies avoiding this area altogether. 
On the other hand, the argument of the 
therapeutic applicability is often equally 
bluntly refuted by adversaries of heSC 
research in order to avoid such moral 
pressure. their reasoning is that the po-
tential therapeutic applicability in the fu-
ture is of limited value now, and only of 
theoretical nature concerning the balance 
of values. the above views are extremes, 
and each indication needs to be evaluated 
individually for a reasonable judgment.
What are the facts about the therapeu-
tic potential and why is this issue so im-
portant? Concerning the latter question, 
we need to recall that the stakes are high 
in this debate. It is about human living 
material in one or the other form, which 
is used for research, and which is derived 
from material, which at some time had a 
certain potential of becoming a human 
being. A value of equal moral weight 
would be the healing of sick human be-
ings, i.e. the prevention of pain, suffering 
and death. the ethics of healing is as old 
as our culture, and many religions teach a 
duty to help and heal. this requirement 
to heal, whenever possible, is particularly 
strong in religions related to or based on 
the old testament of the bible. In the Jew-
ish tradition, for instance, the primary 
importance for saving lives and helping 
suffering patients takes precedence over 
the fears generated by modern genetic 
and reproductive research. Provided that 
new technologies are applied for medical 
indications and respecting human rights 
and human dignity, it is legitimate to ex-
plore their beneficial potential (Revel, 
2003). therefore, the argument of thera-
peutic applicability has been so much in 
the focus of the heSC debate. In order to 
understand the term “therapeutic poten-
tial” it is useful to look at its three differ-
ent dimensions separately:
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Research on human neurons is extremely 
difficult due to the poor availability of the 
material. therefore, most experiments to 
test toxicity have relied on animals or 
animal material, and this has sometimes 
led to detrimental erroneous conclusions 
(see thalidomide). Another illustrative 
example is cardiotoxicity (in particular 
toxicity of drugs that cause changes of 
the heart beat). this is frequently associ-
ated with drugs that interact with the so-
called heRG potassium channel on the 
heart. It is likely that in the near future, 
heSC-derived cells may be substituting 
the current assays performed with pri-
mary porcine or rabbit cardiomyocytes 
(heart muscle cells). Such cells can now 
be generated from heSC with almost 
100% purity, and these cells have been 
shown to function in the heRG test (xu 
et al., 2008). 
3.7  Issue 15: Scientific progress
A value different from therapeutic use, 
is scientific progress. Scientific progress 
may eventually lead to improved thera-
pies, but there is only a loose and rather 
indirect connection between the two. 
Still, everyone born in rich industrialized 
societies has benefited from the fruits of 
past research and it is scientific research 
that will discover ways of combating 
the dangers to come. Independent of the 
practical benefits of science, the freedom 
of scientific research per se is a basic civil 
and political right because it is a dimen-
sion of freedom of thought and freedom 
of speech. thus, a high value is at stake 
here too, although the weight of the argu-
ment is less obvious to the public than the 
therapeutics rationale. Scientific progress 
remains a very theoretical argument for 
those not deeply involved in science. 
therefore, the importance of the issue 
is underestimated. As scientific progress 
is no good political argument, it is not 
promoted as much as it would deserve. 
three lines of argument illustrate the im-
portance of basic research with heSC: 
• The first refers to developmental biol-
ogy. It is one of the wonders of nature, 
that on the one hand, a complete animal 
or human being can develop from a zy-
gote, and that on the other hand stem 
cells can retain infinite replicative ca-
pacity in an undifferentiated state. We 
3.6  Issue 14: Benefit to animals
It has been argued that heSC can by 
no means be used to substitute animal 
experiments. this would mean that ex-
periments are instead performed on “hu-
mans”. However, this argument contains 
a misconception. the testing of toxicity 
on human cells allows man to take re-
sponsibility for himself without relying 
on animals and their suffering. It would 
not be a substitute, but an entirely differ-
ent, and possibly better approach. Hu-
man cell-based in vitro methods would 
fully correspond to the new vision of a 
mechanistically based toxicology (leist 
et al., 2008b; Hartung and leist, 2008) 
that implies higher financial efficiency 
of the procedure and improved safety 
for mankind. For instance the eU project 
eSNAtS has been started with the goal 
to develop novel heSC-based alterna-
tive test systems for drug profiling. The 
program involves small-to-medium sized 
biotechnology companies, around 2 
dozen research laboratories throughout 
europe and a steering committee giving 
professional input on industrial applica-
bility, ethical questions and utilization 
of discoveries. the project also involves 
major national and european authori-
ties involved with finding alternatives to 
animal experimentation. this is a logical 
consequence of a line of research that has 
shown that 3R (reduction, replacement, 
and refinement of animal experiments) 
methods have been astonishingly suc-
cessful and can sometimes yield better 
data than animal-based tests (Hartung, 
2001, 2007a, 2007b, 2008; leist et al., 
2008b). heSC-based test systems could 
contribute to such a strategy of safety 
testing with fewer animals, and with data 
more relevant to humans, and more based 
on sound science. this concept should by 
no means be mistaken (or distorted) to 
imply that animal experiments would be 
substituted by embryo research. typical 
examples for the application of heSC at 
the moment are in the field of develop-
mental neurotoxicity. the thalidomide 
catastrophe showed that animal models 
can be very poor predictors of human 
developmental toxicity. Accordingly, a 
lot of focus has been on the development 
of eSC-based test systems, initially on 
murine cells, and in recent years also us-
ing human cells (Pellizzer et al., 2005). 
eS-based test systems (Buesen et al., 
2004; Seiler et al. 2002, 2006; Whitlow 
et al., 2007; leist, 2006). this poten-
tial use applies to many diseases where 
transplantation is not a therapeutic op-
tion, and thus may accelerate the avail-
ability of new and safer drugs soon. A 
special variant of this approach would 
be that disease models can be devel-
oped on the basis of human genetic de-
fects (Pickering et al., 2005). So far, this 
approach has been relatively neglected 
in the ethical debate. For instance, the 
companies using heSC-based systems 
for drug discovery will not only do this 
for the benefit of mankind and for the 
commitment to healing, but also for the 
profit of their shareholders. It will be 
difficult to dissociate one from the other 
and to fit this into an equation balancing 
the different values at stake.
3.5  Issue 13: Benefit to mankind
the healing argument falls within a larg-
er category of “being of benefit to man-
kind”. Healing is only one side of the 
coin that represents overall public health. 
the other side is prevention of damage 
and disease. If the latter is successful, 
healing becomes obsolete. If the latter is 
neglected, healing can only mitigate the 
consequences, but not prevent suffering 
to its full extent. An application of heSC, 
different from therapy, but still of high 
moral value, would be the prevention of 
damage. A typical example for this would 
be the use of heSC-based systems to de-
tect environmental toxicants that would 
cause human developmental toxicity. In 
contrast to the therapeutic use, results of 
this research would be expected in the 
very near future. Concerning the balance 
of values, it may be argued that preven-
tion of damage is of lower moral status, 
than healing, as the former only ad-
dresses the potentiality of damage, while 
the later addresses an existing problem. 
However, the opposite argument would 
also make sense: such that it is better to 
prevent damage than to heal what is left 
over after it occurred. this issue is a gen-
eral and continuous dilemma of health 




search is perfectly acceptable in Israel 
and also in relatively religious Moslem 
societies. Israel has a front role in heSC 
research and Iran for instance has gener-
ated its own heSC lines (Baharvand et 
al., 2004). 
the Protestant Churches differ in their 
viewpoint, ranging from relative accept-
ance, e.g. by the Anglican Church to ab-
solute rejection by others. the Catholic 
Church has an interesting history of de-
fining the beginning of human life and 
moment of ensoulment, which moved 
closer and closer to the zygote as more 
biological knowledge was accumulated. 
The definition of Thomas Acquinas, 
which was used for centuries (and reach-
es back to ideas of Aristotle), referred to 
an ensoulment at day 40 after fertilization 
(day 80 for female fetuses). In 1869, the 
papal bull Apostolicae Sedis by Pius Ix 
moved the time point of ensoulment and 
start of full human dignity to the stage 
of zygote formation. The new definition 
incorporated contemporary scientific 
knowledge (discovery of the biology of 
conception after the microscope was in-
vented). At present, the modus operandi 
of the Catholic Church (e.g. the adher-
ence to dogmata) slows further develop-
ments (i.e. adaptation of the time point of 
ensoulment) based on more recent scien-
tific insights and progress in reproductive 
technologies.
More liberal Western countries such 
as Australia, Sweden, and the UK ac-
cept research with heSC including the 
generation of new heSC lines. this is 
also deemed acceptable in a number of 
Asian countries (India, China, Singapore, 
South Korea, Japan), but research is al-
ways controlled to varying degrees. the 
situation in the US is especially inter-
esting. Federal funds cannot be granted 
for heSC generation for ethical reasons, 
but there are few limitations on research 
carried out with private funding. For in-
stance, the US state of California is heav-
ily sponsoring heSC research through 
raising of private funds (“proposition 
71”) and the formation of a privately 
founded designated heSC institute, the 
CIRM (trounson et al., 2008).
looking at this heterogeneous map, it 
is difficult to identify a clear ethical pat-
tern. It is likely that cultural traditions 
step of the natural product therapy. In 
the same vein, we no longer expose 
printers (type setters) to lead poisoning, 
as was common before the introduction 
of computerized and other “cold-type” 
printing techniques some decades ago, 
but – again – we would not have these 
modern techniques (and probably none 
of our culture at all) without a long pe-
riod of printing by mechanical letter 
setting.
• In the long run, purely scientific progress 
often finds the most astonishing practi-
cal applications. In many cases, direct-
ed research would never have resulted 
in these discoveries. Without basic, 
non-directed research of the past, many 
practical applications of today would 
be unthinkable – and (as mentioned 
above) without basic research today, we 
will not solve the (yet unknown) chal-
lenges of the future (Solter, 2006). One 
of the oldest examples from the field 
of medicine are dissections of bodies. 
these were forbidden for about a mil-
lennium as “basic research that may 
violate the dignity of man or the respect 
for God”. In the end, legalization and 
moral acceptance of this research fa-
cilitated progress in surgery and other 
disciplines that could never have been 
anticipated or even dreamt of before.
4  Features of the discussion and 
the way of argumentation
In the debate on heSC, high values are 
at stake. the discussion is not only based 
on the exchange and consideration of 
logical arguments, but it is also used to 
attract followers, voters and members (of 
parties, churches and research organiza-
tions). Accordingly, also techniques of 
manipulation, appeals to the unconscious 
and references to historical events are 
used. these need to be understood and 
dissociated from the factual debate.
4.1  Issue 16: Historical and 
cultural aspects
the approach to the use of stem cells is 
often influenced by the culture of a soci-
ety and its dominant religion and church 
organizations. For instance heSC re-
can study these two phenomena in flies 
and worms, but ultimately the most 
exciting results can be expected from 
studying man. Other “model organ-
isms” are only poor substitutes, since 
development of human beings differs 
in various essential aspects from the 
development of other species. We will 
not understand our own development, if 
we ban this research. We will not under-
stand what makes our own stem cells be 
a stem cell, and what determines their 
potency for differentiation, and neither 
will we understand why differentiation 
is mostly a one-way road, and how can-
cer cells find a way to reverse the di-
rection on this road…. It is an inborn 
desire of man to understand what he/
she is made of and comes from. thus, 
it appears to be against human nature 
to limit research into these topics, even 
though there may be no immediate ap-
plication.
• The second example refers to the impor-
tance of intermediate steps in the gain 
of knowledge. At some, not too distant 
future, heSC cells may be generated 
independently of the use of embryos. 
then, the ethical issues discussed here 
would become largely obsolete. We do 
not know whether this will happen, but 
encouraging scientific data indicate that 
it may become possible (see issue 32 on 
iPS). Still, we know one thing for sure: 
Without research in heSC cells and 
without the knowledge gained there 
from, this step would never happen! At 
present, heSC derived from zygotes are 
the golden standard by which all other 
eS cells are measured by as they come 
into being. We would not learn to repro-
gram other cells for therapeutic and sci-
entific purposes, if we would not know 
what to reprogram them to. this progress 
via essential intermediate steps has hap-
pened dozens of times in the history of 
science and culture. We no longer inject 
people with extracts from bovine brain 
or porcine pancreas to treat dwarfism or 
diabetes. We would risk the transfer of 
retroviruses and infectious agents caus-
ing spongiform encephalitis (mad cow 
disease). Instead we produce clean re-
combinant human growth hormone and 
insulin. However, we would never have 
arrived there without the intermediate 
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the German parliament that objected to 
the new legislation on import of eS cell 
lines published a booklet “Against re-
search consuming embryos”, although it 
was absolutely clear that embryos have 
never been and will not be used for re-
search in Germany, and that the change 
of the import law for eS cell lines would 
also not lead to more or less embryo con-
sumption, neither inside nor outside of 
Germany. extremist objectors even use 
the words “killing” and “murder” for the 
generation of heSC cell lines, and we 
have detailed in issue 1 why this termi-
nology is inappropriate. the expression 
“therapeutic cloning”, which is used to 
describe nuclear transfer, should also 
figure as a deliberate dysphemism, con-
sidering the fears and the relative lack of 
exact information of the public with rela-
tion to cloning and the negative image of 
the word. In conclusion, it is useful and 
highly advisable to agree on a common 
unbiased terminology avoiding any dys-
phemisms or euphemisms when entering 
into a public debate on heSC research or 
related issues.
4.4  Issue 19: Different logics 
may apply
to understand the discussion on heSC 
cells, it is important to recognize that de-
pending on the viewpoint, different “log-
ics” may apply – and these different log-
ics may all be correct. thus, both sides 
may be right, even though they disagree, 
and acknowledgement of this situation 
should promote tolerance towards the 
other point of view. the correctness of 
different “logics” is not only based on dif-
ferent initial assumptions. It is also pos-
sible because what is colloquially called 
“logics of the argument” does not follow 
strict rules of deductive logics. Instead, 
the arguments used in public discussions 
are mostly built on chains of reasoning 
that include intuition, emotions and rela-
tively non-compelling associations. 
Pseudo-logics and syllogistic (i.e. an 
argument where one proposition is sim-
ply inferred from two premises) mistakes 
are very common, and they are acceptable 
when their use is involuntary, due to strong 
emotional involvement or due to a lack of 
formal training. However, the situation is 
pery slope argument will only polarize 
the debate and prevent a constructive 
compromise. It is a matter of practical re-
sponsibility to also deal with unwelcome 
facts instead of just defining them away 
(see issue 24).
4.3  Issue 18: Rhetorical variants 
All classical rhetorical means are used 
in the public debate on heSC research. 
therefore, the vocabulary used frequent-
ly allows the identification of the stand-
point of the speaker. If someone claims 
that he/she is for the protection of life, or 
belongs to a pro-life group (in US) and 
that human dignity must not be violated, 
one can conclude that the person objects 
to heSC research. Why is this so? Most 
researchers and supporters of heSC re-
search would themselves fully agree with 
the statement, and they are also pro life 
(= supporting life). the problem is that 
these statements are not meant as state-
ments of the content, but they are simple 
truism, that are usually used by objectors 
to put moral pressure on those accepting 
heSC research. It is an obvious accusa-
tion and attack that the others may not 
respect these principles. And use of such 
a truism often results in the assignment 
of moral superiority to those objecting 
to heSC cell research. Particular expres-
sions are used to enhance fears by making 
things sound worse than they are (dysphe-
misms) or to make bad things look nice 
(euphemisms). A typical dysphemism 
was used 25 years ago, at the beginning 
of IVF. the procedure was not named as 
such but referred to in dysphemistic man-
ner as bébé éprouvette (F), bambino in 
provetta (I), Retortenbaby (D), test tube 
baby (UK) – all expressions that evoked 
negative associations from A. Huxleys 
novel and that have now nearly entirely 
vanished, as the technology has become 
common and millions of children have 
been born and live amongst us.
Supporters of heSC research can be 
observed to use euphemistic words (such 
as the complicated term “pro-embryo”). 
this is done to avoid the use of the word 
embryo when describing the procedure of 
“cell line derivation”. On the other hand 
dysphemisms are heavily used by objec-
tors of heSC research. the members of 
and sometimes political influence of 
individuals (like A. Schwarzenegger in 
California) have at least as much impact 
as elaborate ethical considerations.
4.2  Issue 17: The slippery slope 
issue
Sometimes reference to historical roots 
can pose significant discussion hurdles 
– intentionally or unintentionally. One 
of the frequent “show stoppers” is the 
slippery slope argument (“Dammbruch-
argument” in German). this metaphor 
refers to a situation where the first small 
step irrevocably leads to an uncontrolla-
ble sequence of downstream events that 
end in a catastrophe or at least a difficult 
situation. With this approach it is easy to 
argue against anything, even though this 
“thing” may be acceptable on first sight 
to most people. the “trick” is, to link the 
first step to dire consequences further 
down the road, and make the connection 
of the steps look logical. even though sci-
ence has historically been seen mostly a 
steady stairway up to higher insight and 
better conditions of life for man, each of 
the new steps upwards has been called 
at some point by fundamentalist groups 
“the first step on a slippery slope down-
wards”. 
the slippery slope argument is then 
often reinforced by parallel references, 
whether they are relevant or not. Fre-
quently encountered examples are refer-
ences to euthanasia or other cruelties in 
the Nazi regime or the elimination of un-
fit children by the Spartans in old Greece. 
Another variant is that the blame is put 
on the acceptance of IVF as the first step 
on a slippery slope and the basis for the 
current heSC dilemma. From this argu-
ment, it is only a small step to seeing 
any sort of scientific and technological 
progress as such, as the first step on a 
slippery slope. the slippery slope argu-
ment is not necessarily a wrong argument 
in some ethical debates. But it is a dan-
gerous argument, as it brings all discus-
sions to a halt without real reflection on 
the problems and the potential solutions. 
especially in the current heSC discus-
sion, with widespread public acceptance 
of IVF and heSC generation and related 
methods having progressed so far, a slip-
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ing compared. In one case (death of ba-
bies), the personhood was already there 
before (!) death. Nobody would ever 
contest that. thus death of babies is not 
related to the continuity discussion at all. 
In the case of blastocysts, the situation is 
entirely different. If one does not accept 
the purely religiously-based argument of 
ensoulment at gamete fusion, then conti-
nuity and potentiality between the blasto-
cyst and a later human being must be es-
tablished for the assignment of partial or 
complete personhood to the early form.
4.5  Issue 20: The definition of 
ethical and unethical
the fate of many new technologies has 
been to be first considered unethical and 
then slowly becoming less unethical and 
eventually becoming acceptable or even 
desirable. One wonders whether this is 
going to happen to heSC research, and 
what determines such changes.
One key factor is certainly whether 
there is demand and hence a market for 
this technology. Stem cell-based technol-
ogy will most likely be broadly accepted 
if a successful application can be found, 
and it will vanish by itself, if this does 
tween grown up people and early em-
bryos and generates an emotional link, as 
everybody can refer to oneself as having 
been such an embryo. Once this state of 
mind has been set, the viewpoint is then 
reversed: “thus, every embryo will be 
a person unless he/she is actively inhib-
ited in this development” and “If every 
embryo will be a person, it also should 
be granted full human dignity”. the re-
versal of this conclusion is logically 
just a rhetoric trick, and biologically 
not allowed (as detailed in issue 4), but 
this rhetoric trick is frequently used by 
heSC research opponents. It is similar to 
transforming “all cherry trees have been 
a cherry once” into “all cherries will be-
come cherry trees…”. 
An argument mentioned in issue 7 (ni-
dation) is also a pseudo-logical error. It 
is claimed that death of most blastocysts 
before nidation has no role in the conti-
nuity and potentiality discussion, as we 
also do not contest human personhood in 
situations where a high fraction of babies 
die after birth (as was common in most 
Western countries up to 100 years ago). 
there appears to be something logical 
in this argument, until one realizes that 
two entirely different situations are be-
different when logical mistakes are pro-
duced on purpose for manipulative reasons 
by persons skilled in the art of logic rea-
soning. A typical pseudo-logic line of ar-
gument would be the following: Statement 
1: “We need to protect the weak”. Right, 
it is a fundamental value of democracy to 
protect the weak (see issue 14). Statement 
2: “embryos are weak”. Right, cells and 
embryos cannot lobby for themselves and 
they are vulnerable. Now different con-
clusion may be drawn from statements 1 
+ 2. Conclusion 1: “We need to protect 
embryos“ is a sentence obeying the rules 
of syllogism, i.e. it follows logically from 
1+2. As a consequence of this conclusion, 
embryo protection laws were passed in 
many countries. An alternative conclusion 
also encountered during discussions is 
conclusion 2: “therefore research on stem 
cells must be prohibited”. this conclusion 
harbors several logical misconceptions. 
“therefore” is a wrong term, as conclusion 
2 does not result logically from sentences 
1 and 2. the exclusive term “must” is also 
wrong. Prohibition of stem cell research 
would only be one of many possible ways 
to protect embryos. Without the words 
“therefore” and “must”, the implication 
and relation of the major meaning-bearing 
words “stem cells” and “prohibited” is not 
defined. However, “prohibition” stands 
close to “stem cells” and therefore gives 
an erroneous (and manipulative) impres-
sion of a logical link (=pseudo-logics). A 
third misconception is particularly decep-
tive. Sentence 1 is “We need to protect the 
weak”. It does not say “the weak persons”, 
but in our mind we easily add “persons”. 
However, if sentence 2 was “animals are 
weak”, then the syllogistic conclusion 1 
would be “We need to protect animals”… 
we leave everybody to their own thoughts 
here, but one implication is, that “embryo 
protection” as in conclusion 1, does not 
imply that embryos are persons. However, 
in debates that are not logically clean this 
is often surmised. the rationale for the 
deliberate use of such pseudo-arguments 
may be the recruitment of followers for a 
certain cause. 
Another typical pseudo-logical manip-
ulation is the reversal of statements that 
cannot be reversed. For instance, “every 
person has been an embryo once”. this 
is a universal statement that is always 
correct. It establishes a connection be-
Fig. 4: The development of scientific/technological understanding and the 
maturation of the ethical debate
Scientific progress is shown to occur in steps (blue). Bioethics as academic discipline 
develops in reaction to scientific progress. The process of consolidation and progress 
in this discipline is smoother than in science (red). This creates zones of tension, when 
science advances into new areas where the ethical debate is not yet settled. At present we 
are in such a stage with respect to hESC research.
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or being pure utilitarians with no concern 
for the dignity of man. If these attitudes 
are avoided the whole debate can be 
brought to a more constructive direction. 
Most Western societies are built on the 
principle of pluralism, which forbids by 
itself the ethical hegemony of one group.
4.7  Issue 22: Mistrust and 
irrational fears
In order to settle the controversies around 
the use and creation of heSC, it is im-
portant to understand all the reasons that 
form a basis for objections. One of the 
reasons is an inborn fear or mistrust of 
complex and powerful systems that we 
do not understand intuitively, and that are 
out of our control. Scientific laboratories 
and what happens in them, behind their 
closed doors, are such a system for much 
of the public. Moreover, the topic of stem 
cell generation and use is often immedi-
ately associated with the topic of clon-
ing and de novo generation of strange 
human-like beings. this has been a topic 
of horror since Mary Shelley’s Franken-
stein, H. G. Wells’ Island of Dr Moreau 
and Aldous Huxley’s Brave New World, 
and misconceptions and fears have been 
enhanced and promoted by dozens of 
Hollywood films. No rational argument 
will be strong enough to wipe away irra-
tional fears due to new technologies. 
However, some groups use this situ-
ation for their own agenda. In a com-
plex world, that has become difficult to 
conceptionalize and understand, sim-
ple concepts are offered, and these are 
usually associated with a rejection of 
all scientific progress. This fundamen-
talism is no solution, but it is growing. 
the big Christian churches have a huge 
responsibility here, not to jump on this 
bandwagon and to offer the comforting 
simplicity of technology rejection as a 
solution to the intricacies and complexi-
ties of the world. What else can be done? 
the alternative approach is time, teach-
ing and transparency. the more educa-
tion, the more understanding. the more 
understanding, the fewer uncontrollable 
complexities. the more transparency, 
the fewer irrational fears. the broader 
the common knowledge, the less risk for 
individual and public opinions to be ma-
nipulated! 
the ethical discussion of new develop-
ments, maturation of thoughts and in-
corporation into the existing framework 
follows different kinetics. It takes time, 
is more continuous and has to react to 
what is happening in science  (Zoloth, 
2002). As a consequence, ethical discus-
sion lags behind during periods of rapid 
scientific change, and this generates 
controversies and discrepancies, which 
are in most cases resolved by time, as 
bioethics catches up again with the state 
of science. Presently, a scientific step is 
happening in the field of stem cells and 
it may be speculated that what appears 
so controversial today, will be in line 
with main stream ethical standards in 
10 years time (Fig. 4).
4.6  Issue 21: The right to  
be right
If one accepts that different logics may 
apply and that ethics has a certain dy-
namics of its own, then there is a good 
basis for tolerance in the heSC debate. 
However, this situation and the poten-
tial for reasonable compromises are 
jeopardized, if different sides claim a 
natural right to be right. For instance the 
churches often claim authority in moral 
questions. even more, they claim that re-
ligion is the only means to give meaning 
to life and to answer the question of why 
we exist. From this, it is only a small step 
to claim the right to define what is right 
and wrong for human beings attempting 
to live a meaningful life, and finally the 
absolute moral authority on stem cell 
issues is derived. In a democratic and 
pluralistic society, where members of 
different religions, and cultures coexist, 
such an attitude is not helpful for produc-
tive discussion. Scientists, on the other 
hand, claim authority on all technical 
knowledge and a superiority of technical 
knowledge over other forms of insight. 
Some of them tend to display a very nar-
row “technocratic” viewpoint devoid of 
social, religious or ethical aspects. this 
attitude must fail terribly, when it is ap-
plied to ethical standpoints. things be-
come worse, when the right to be right 
is used for accusations, such as churches 
being hostile to science and scientists do-
ing things just because they are doable, 
no matter what consequences there are, 
not happen, for instance when it is com-
peted out by another technology. Can the 
market really define whether something 
is ethical or unethical?
• Shift of attention: Possibly, we are ob-
serving only an apparent change. Scien-
tific method is based on the principle of 
falsification (Popper, 1934). Thus it is 
straightforward to show that something 
is unethical (one single condition lack-
ing). It is however much harder to show 
that something is ethical (all conditions 
fulfilled without exception). A single 
scratch in the image suffices to render 
it unethical again. With emerging tech-
nologies, many different societal and 
religious groups try their claws, and it is 
unlikely that there is not one or another 
aspect of the new technology that may 
generate ethical conflicts. With increas-
ing success and establishment of the 
technology, it is more and more taken 
for granted and less targeted by ethical 
attacks. thus it does not become neces-
sarily more ethical, but the scrutiny and 
attacks diminish. An apparent change 
has taken place, but it only reflects a 
shift in attention. A typical example 
would be IVF. 
• In addition to the shift in attention, the 
evaluation of what is ethical is depend-
ent on the societal consensus, which 
changes with time and situation. Beat-
ing of children is an example where 
we have seen large changes in attitude 
e.g. in europe. Or gluttony (overeat-
ing), which depending on the society, 
has been considered unethical (mortal 
sin), neutral or positive. terrorist laws 
restricting individual freedom are ac-
cepted as necessary or rejected as un-
ethical, depending on the actual politi-
cal situation and state of threat. thus, 
it is common for ethical judgments to 
change over time and this will most 
likely happen for heSC research, once 
a beneficial application has been found 
(see balance of values, above).
• The above issues are theoretical con-
siderations of what may happen to the 
public evaluation of heSC research. 
Furthermore, a general practical phe-
nomenon can hardly be avoided: sci-
entific progress often occurs in steps 
(Kuhn, 1962), i.e. not much happens for 
a while and then suddenly a new tech-
nology develops that pushes progress. 
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without any neural system, and with no 
chance to become a human being (because 
its “parents” have decided so) really need 
significantly more ethical protection than 
the organs of an adult man (protected by 
the transplantation law) who had a motor-
bike accident? If we were less politically 
correct, we may go on to ask more gener-
ally, whether the concept of uncondition-
al human dignity really holds in practice 
in its extreme interpretation as detailed 
under issue 11, or whether it is an expres-
sion of the luxurious situation of our life 
combined with hypocrisy. let’s initially 
look at a single defined example to illus-
trate the thought: “triage”. this is origi-
nally a military term (now also applied 
during major catastrophies, i.e. hurricane 
Katrina) used for the process of defining 
the wounded that should be treated after 
a battle, when only a limited number of 
doctors or amount of drugs is available. 
In practical terms, someone has to take 
this decision, even though everybody has 
basically the same right to be treated. 
In civil terms we find similar examples 
when someone decides who has a right to 
obtain a transplant organ. these are not 
active killing decisions, but it is accepted 
that the ones that have been chosen not to 
be treated will die. 
In other situations, loss of human lives is 
knowingly accepted if the active decision 
to “send people into their death” is just suf-
ficiently diluted by some random principle 
of who will actually die, or if it is balanced 
by other interests and values: One example 
would be the construction of huge physical 
structures that inevitably leads (or lead) to 
a significant number of deadly accidents 
(for instance, building the Gotthard tun-
nel took 177 lives, yet, we find it ethically 
acceptable to use the tunnel). Also, we are 
used to a death toll by car traffic of tens of 
thousands per annum without questioning 
the actual traffic regulations and driving 
our cars; all clinical studies conducted to 
introduce new treatments inherently carry 
a risk for the participants to be harmed or 
even die; military commanders sending 
troops to Afghanistan, Iraq, Falklands … 
or commanders of fire brigades in charge 
of difficult tasks know that (statistically 
speaking) some of their crew will definite-
ly be killed. 
While we are using time and energy dis-
cussing the ethics of heSC research based 
compromise is hard to negotiate. What is 
the background for this attitude? In many 
countries, in and outside europe, conserv-
ative circles are strongly influenced by 
the Catholic Church. In this organization, 
the principle of pluralism is not adhered 
to as strongly as in other cultural settings. 
the freedom of thought in this institution 
is naturally limited by dogmas that need 
to be adhered to, and by the belief in the 
infallibility of the opinion of the pope, 
which makes changes of opinion difficult. 
4.9  Issue 24: Practical 
responsibility
An important issue determining the for-
mation of opinions, including the one on 
heSC, is the link to responsibility and 
power. It is easy to object to anything 
that is ethically difficult, if one does not 
have to take the responsibility for the 
consequences of the denial. For instance, 
young people and youth organizations of 
parties and societal groups often object 
to societal rules and guidelines. their at-
titudes and also their practical behavior 
often changes radically when they take 
responsibility in the function of manag-
ers and politicians. then, they may come 
to different conclusions, because many 
issues with all their consequences need to 
be balanced. With this situation in mind, 
one has to take a closer look at the groups 
objecting to heSC research. Some oppo-
nents do not feel any difference in their 
lives, whether science advances or not. 
For them, scientific progress is not an im-
portant value as such or something that 
has importance for their lives. they either 
lack the necessary historical understand-
ing and general insight, or they object to 
technological development in principal 
for a number of diverse reasons. Others 
are just innocently ignorant and accord-
ing to the motto just pain, no gain, these 
must naturally come to a judgment that 
is critical towards the use of heSC. Also, 
an exclusive focus on the fate of the soul 
after death can detract from interests in 
science for the body before death.
Under this chapter of “practical re-
sponsibility” also a number of provoca-
tive thoughts shall be presented, not as 
fixed opinions, but rather as a stimulus 
and food for thought. to put it frankly, 
we may ask: does a tiny ball of 200 cells, 
Scientists especially must not forget 
that naked information needs to be trans-
formed into knowledge and knowledge 
into confidence. Generation of confi-
dence also requires experience, and both 
take time. It is important to realize, that 
this applies to highly educated scientists 
as well as to the general population. Most 
scientific revolutions have also been ob-
jected to by the other scientists of their 
time (otherwise they would not have been 
called revolutions), and only time has led 
to confidence and acceptance. With the 
emergence of heSC-based test systems, 
it is important to plan in advance for de-
voting time and creating opportunities 
to engage in public discussion. A full 
implementation of the technology will 
only make sense when its time has come, 
and society has matured to accept heSC-
based test systems. Both promoters and 
objectors of heSC research should use 
the time for a constructive dialog.
4.8  Issue 23: The question of 
opinion formation
to understand the evolution of the debate 
on the use of heSC cells, it is useful to 
briefly look at some aspects important 
for the formation of opinions in general. 
From many examples (internet shopping, 
IVF – assisted reproductive technologies, 
heart transplants …) we know, that what 
is commonplace today, used to be com-
plex, unknown, dangerous and stressing 
only some years ago. Not only the exter-
nal situation can change, but intuition and 
confidence grow with use and time. This 
means that one can naturally come to a 
different conclusion if one re-evaluates a 
situation now, as compared to some years 
ago. this sounds trivial, but has caused so 
many problems in the heSC debate (and 
elsewhere). For instance, certain mem-
bers of parliament and of the protestant 
church in Germany had objections to the 
use of heSC lines in the 1990s, but were 
more open to accept a limited use of this 
technology in 2008. Conservative cir-
cles have called that change of attitude 
“moral inconsistency” and implied a lack 
of character. It appears difficult for these 
circles to accept that an ethical evaluation 
can change when the circumstances and 
understanding change. In an atmosphere 
where opinions have to remain fixed, 
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is a published, generally-accessible 
method, generation would also not be 
inventive and novel (if the WARF pro-
cedure is identically copied), and thus 
not patentable in the country were the 
new eSC are generated. thus, it is like-
ly that many eSC lines are not gener-
ally protected by patents. 
• It is important to distinguish the protec-
tion by patents from ownership of the 
material. A cell line can be owned by 
the producer according to national leg-
islation on private property. If such ma-
terial is given away, a material transfer 
agreement (MtA) can be negotiated be-
tween the recipient and the owner. this 
has nothing to do with patents and IPR, 
but is a purely private contract on con-
ditions of use of the material. “Materi-
al” is used here in a purely legal sense. 
the issue on how far something derived 
from human beings can be “owned” and 
“traded” is ethically complex and does 
not only involve heSC. One has to bear 
in mind that in many areas marketing of 
human cell lines, tissues and other hu-
man material has had a long tradition. 
• The owner of a patent can allow others 
to use the invention (e.g. heSC line) 
under certain conditions. this permit is 
called a license and can be exclusive or 
non-exclusive. For instance WARF is 
non-exclusively allowing other compa-
nies to use their cell lines and technol-
ogy for commercial purposes against a 
license fee of e.g. 125,000 $. 
• Often MTAs also contain rules on how 
the intellectual property rights are han-
dled, when an invention is made while 
the “material” was used or because the 
material was used, but this has noth-
ing to do with patents on the mate-
rial (heSC) itself. It is a purely private 
agreement between the parties involved 
and to be freely negotiated.
heSC pose a particular ethical problem 
for the handling of intellectual property 
rights, as they border upon the question 
of how far life, and especially human life 
should be patentable. In europe, Article 
53(a) of the european Patent Conven-
tion (ePC) precludes the patenting of 
inventions whose exploitation would be 
contrary to “ordre public” or morality. 
One of the most prominent examples of 
application of this paragraph is the “ed-
er, carries full rights to decide over the 
fate of her potential future child. the sit-
uation becomes even more striking when 
one looks at so-called “criminogenic in-
dications” as for instance under German 
or Polish law. If there is a possibility that 
the pregnancy is due to a rape, then the 
embryo may be killed…. How does this 
fit in with the claim of unconditional in-
violability of human dignity?
4.11  Issue 26: Intellectual 
property rights
New technologies usually involve intel-
lectual property rights (IPR). the issue 
of IPR is a potential ethical dilemma in 
the field of hESC-based test systems, and 
it is often an area of great insecurity for 
the research community involved. Intel-
lectual property (e.g. inventions) is often 
protected by patents (i.e. a temporary, 
and nationally-limited right to prevent 
others from using it). A frequently dis-
cussed series of such patents (#5,483,780 
and #6,200,806) is held by the Wisconsin 
Alumni Research Foundation (WARF) 
and describes the culture and derivation 
of heSC and the cells themselves (Plom-
er et al., 2008). these patents are based 
on pioneering work by Jamie thompson 
at the University of Wisconsin. 
In general, both procedures and cell 
lines themselves can be patented. In 
both cases, it is important that something 
novel was done, and an inventive step 
was involved in the procedure. If a pro-
cedure (e.g. to make heSC) is patented, 
then also the product that was generated 
with this procedure is protected. this has 
a number of important practical implica-
tions that may be used as examples for 
other cases and to help clarify uncertain-
ties in the research community: 
• The WARF cells are patent protected 
in the US (where the patents are valid) 
even though the patents claimed only a 
process of generation and culture of the 
cells, and not the composition of matter 
directly.
• If someone else, in a country where the 
patents are not valid (e.g. in Germany 
or most of Asia) would use the “WARF 
method” to generate new eSC, this 
would not be a violation of patent laws. 
these cells would be free of the WARF 
patent. However, as the WARF method 
on left-over IVF embryos, 750 million 
real people are suffering from hunger and 
more children die of its consequences in 
one day, than the total number of embryos 
ever used for research. Who takes care of 
the dignity here? Children should not go 
to school hungry, and hide their hunger 
because it is embarrassing. this happens 
in our own countries and is a violation of 
dignity of human persons, whose actual 
potential is being limited. We rarely have 
podium discussions and parliament de-
bates on these topics. Why is this? Could 
it be that we have lost perspective? Could 
it be that we generate artificial problems 
about heSC research instead of solving 
real problems of real people? 
4.10  Issue 25: The bathtub 
function of embryo rights
the issue of practical responsibility ne-
cessitates mentioning of a strange phe-
nomenon. the so-called bathtub function 
– first high, then low, then high again. 
this is the protection status of the em-
bryo in some countries, including Ger-
many. Initially, fertilized oocytes are 
highly protected, by stem cell laws and 
embryo protection laws. essentially, at 
this stage blastocysts are given an ethical 
and legal status that is almost compara-
ble to a person. At 5-9 days of age, nida-
tion starts and thus pregnancy officially 
begins. Now abortion becomes possible, 
and killing of the embryo is allowed, or 
at least tolerated. Several weeks (or even 
months in extreme cases when abortion 
of a fetus is medically indicated) later, it 
is forbidden again and the embryo is ful-
ly protected. Where is the legal consist-
ency – and credibility of the practical le-
gal framework – in this bathtub function? 
Moreover, it needs to be mentioned that 
killing of the embryo (after nidation) is 
explicitly allowed under certain circum-
stances. In many countries, the medical 
indication applies, i.e. the embryo may be 
killed if there is a danger for the mother, 
or if the embryo has no good chances to 
develop to a healthy child (which strictly 
speaking applies to all non-transplanted 
blastocysts by default). In the case of 
abortion, the issue of dignity is handled 
pragmatically and very praxis-oriented, 
and not as would be required by theory. 
Also, here the mother, and only the moth-
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the development of new therapies. the 
translation of basic heSC research into 
practical applications is an extremely 
expensive enterprise with a high attri-
tion rate and many risks of failure. lack 
of patent protection would deprive phar-
maceutical companies of their incentive 
to engage in development of new heSC-
based models, test-systems and therapies. 
It is interesting to have a closer look at 
the fate of the above described cell lines 
covered by WARF patents. these have 
been given to more than 400 academic 
labs basically free of cost, as long as they 
are used for basic research and not com-
mercialization. this example illustrates 
well that academic research is not neces-
sarily limited by patents.
Many people are particularly con-
cerned when potential therapies are being 
patented directly. this appears unethical 
on first sight, but requires a differenti-
ated approach. For instance, we are well 
accustomed to medical instruments and 
drugs being heavily patented areas, and 
know that, also on the ethical side, usu-
ally the benefits of protection are greater 
than the disadvantages. the same applies 
to many diagnostic test kits. For instance 
§2a of the German patent law excludes 
patenting of surgical or therapeutic or di-
agnostic methods, but not that of the ma-
terial used for above procedures. thus, 
an heSC-derived product, which forms 
the basis of a therapy, or the procedure 
to generate this product, can be patented, 
unless it conflicts with the rules of the 
embryo protection law (and its reflection 
in §2 PatG).
A highly important issue for the practi-
cal use and commercialization of heSC 
based technologies and test systems are 
so-called “reach-through claims”. this 
problem often creates large insecurity for 
academic researchers, who have no par-
ticular skills at defining their freedom-to-
operate. even for companies with expe-
rienced legal departments, this can be a 
mine-field and it becomes unclear wheth-
er one is performing illegal research. 
Reach-through claims seek to protect 
things which have not yet been discov-
ered by an inventor, but which might be 
discovered in the future by making use 
of their invention. For instance, someone 
discovers and patents a good method to 
generate neurons from heSC, and then 
However, it is argued here, that the rule 
applies to totipotent stem cells only, 
because these have the potential to de-
velop into all the cells necessary for hu-
man development. On the same grounds 
multipotent eSC are excluded from that 
rule, as they are capable of differentiating 
into all cell types that make up the human 
body but are not capable of giving rise 
to a human being. the key issue is that 
totipotent cells were initially required for 
the generation of heSC, but the ultimate 
decision is still pending in the US. 
In contrast, a clear decision to this re-
spect has been taken in Germany, using 
patent No. 19756864 of O. Brüstle as a 
test case. In the “Brüstle case”, the patent 
office severely limited the scope of the 
patent because of ethical concerns. the 
patent claimed methods to produce neu-
rons and neural precursor cells from stem 
cells. It did not comprise claims on the 
generation of embryonic stem cells and 
mainly described an application of exist-
ing heSC. Nevertheless the reason given 
for the restriction of the claims was that 
at some point hESC had to be generated 
for the patent to make sense. Patenting 
of technology in this area should be pre-
vented in order to preclude commercial 
and economic incentives for the destruc-
tion of embryos. The field of new meth-
ods for stem cell differentiation (as e.g. 
the Brüstle patent) and secondary stem 
cell use is highly active and it remains to 
be seen whether patents in this area will 
stand scrutiny and remain valid in europe 
and its individual countries.
4.12  Issue 27: Commercial 
aspects
the commercialization of heSC is an 
ethical issue that disturbs many people. It 
is often claimed that patents in this area 
prevent the rapid development of test 
systems and therapies for the benefit of 
the general public. this is a particularly 
touchy issue, as the patenting involves 
cells that can at some point be traced 
back to potential human life stages. On 
the other hand, patenting is common-
place in many other research disciplines 
with potential benefits for public health. 
In fact, history has shown that the pos-
sibility to protect important inventions by 
patents has often been a pivotal basis for 
inburgh” patent (european patent No. 
0695351, owned by the University of 
edinburgh after it was granted in 1999). 
the patent concerns a method of geneti-
cally modifying animal stem cells so as 
to give them a survival advantage over 
unwanted differentiated cells. the meth-
od can help to culture and isolate desired 
stem cells. When the patent was granted, 
it was overlooked that the term “animal” 
explicitly included humans, and the pat-
ent could be interpreted as to include 
human eSC. After massive protests ini-
tiated by Greenpeace, the patent had to 
be modified to exclude humans. Also the 
WARF patents are currently a test case 
for european patenting policy. they were 
refused on basis of article 53(a) ePC, and 
the question of whether human embry-
onic stem cells are patentable in the eU 
is currently pending before the enlarged 
Board of Appeal of the european patent 
office. Countries like the UK claim that 
patents must not be refused on moral 
grounds when there is no clear consensus 
among the european states on the moral-
ity of stem cell research and patenting, as 
this would impose undue restrictions on 
countries where heSC research is ethi-
cally acceptable and allowable.
the scope of the ethical issue of stem 
cell patenting is more complex than it 
may appear on first glance. Most patent 
applications do not refer to the cells (i.e. 
the “composition of matter” of particu-
lar human material) themselves, but to 
methods that can be applied to such cells, 
or their precursors or their derivatives. 
the arising problems are illustrated by 
the following case: In the US for instance 
human tissue is not patentable (35 USC 
§101), but the method of making clones 
of genes or cell lines is absolutely patent-
able, as are the cell lines themselves. the 
argument is that clones and cell lines are 
not the original human tissue, but a copy 
thereof, or obtained by a technical pro-
cedure. As heSC do not exist in nature, 
but only in cell culture dishes, they could 
also be deemed patentable (Hansson et 
al., 2007) A similar line of argument is 
e.g. also found in the German patent law 
(PatG §1a). A more specific restriction 
with respect to the use of stem cells in 
the US is Rule 23(e)(1) which prevents 
patenting of a “stage” in the formation 
and development of the human body. 
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lines (Crook et al., 2008). these lines 
underwent stringent pathogen and ste-
rility testing and represent, in principle, 
suitable raw material for future high-
quality test systems and therapeutic ap-
plications.
5.2  Issue 30: So-called adult 
stem cells
Research in the area of adult stem cells 
has been ongoing for many decades. 
therefore the volume and quality of re-
search output, as well as the number of 
laboratories involved is orders of mag-
nitude larger than in the small field of 
heSC. the term “adult stem cells”, as it 
is used in the heSC debate, describes a 
large group of different cell systems. In 
biological terms, adult stem cells are eas-
ily defined as being derived from adult 
human beings. However, in listings of 
alternatives to heSC, often all cells that 
are not heSC are grouped together. For 
instance, human fetuses (embryos with 
developed brain; obtained from abor-
tions) can be used as sources for such 
non-heSC, “adult” stem cells. this is 
not a rare case, but historically one of 
the major sources of stem cell therapy 
besides bone marrow. the cells are still 
used frequently therapeutically, although 
in many cases the value of such treat-
ment is medically doubtful. therapeutic 
centers are mainly located in Asia and 
former member states of the Soviet Un-
ion (Baker, 2005), but they are also used 
e.g. for treatment of Parkinson’s dis-
ease in europe and the US (Hall et al., 
2007, li et al., 2008). these fetal cells 
are not heSCs and are multipotent (for 
instance, a haematopoietic precursor can 
generate blood cells and liver cells, but 
not neurons), but not pluripotent. Here, 
nomenclature confusion becomes a real 
issue, that also has an effect on the eth-
ics discussion. the fetal stem cells (col-
loquially often called embryonal stem 
cells) are certainly not adult stem cells 
and certainly not free of ethical concerns, 
while the heSC are derived from blasto-
cysts (which are not embryos in a narrow 
medical sense). 
the most common sources for adult 
stem cells are the bone marrow and blood. 
Such cells are so-called multipotent or 
oligopotent stem cells, or hematopoietic 
posed to an ethically difficult situation? 
to allow for some judgment on these is-
sues, some of the alternatives are briefly 
described below.
5.1  Issue 29: New cell lines
Bringing heSC into clinical use faces 
great challenges, such as for instance 
providing 100% pure cell populations, 
and guaranteeing safety in terms of con-
tamination with animal products, viruses 
or tumorigenic cells in the final poten-
tial cell therapy product (Hentze et al., 
2007; Vogel, 2005). In this context it 
is important to note that almost all cur-
rently existing heSC lines have been 
derived under conditions that do not fol-
low the guidelines of good manufactur-
ing practice (GMP). For this reason, they 
will most likely never be clinically ap-
plicable in most countries. Furthermore, 
these cell lines were in contact and are 
therefore potentially contaminated with 
diverse animal products or viruses. the 
methods and culture conditions to derive 
the first hESC lines were adopted from 
what was known for mouse embryonic 
stem cells. Therefore, primary mouse fi-
broblasts, generated under uncontrolled 
non-GMP conditions and possibly con-
taminated with unknown pathogens, 
were used as feeder cells. Moreover, 
heSC have been traditionally grown in 
the presence of bovine serum and some 
have been treated with non-GMP grade 
enzymes such as trypsin from porcine 
origin. therefore, the current heSC lines 
grown under these conditions will most 
likely not meet the stringent standards 
for cell therapy products in the USA. the 
situation may be seen slightly differently 
in europe at least for pilot trials for proof 
of principle. Presently, some attempts 
are going on to “clean up” existing cell 
lines. However, should broad therapeu-
tic applications ever become reality, 
new cell lines would most likely be re-
quired. Also for test systems, adherence 
to good cell culture practice guidelines 
(Rispin and Stitzel, 2006; Gstraunthaler, 
2006; Balls et al., 2006) would require 
highly defined cell lines. Several steps 
have been taken in this direction, e.g. by 
Cellartis (Sweden) or eSI (Singapore) or 
Geron and ACt (USA). For instance eSI 
have produced six clinical-grade heSC 
makes claims to include compounds and 
therapeutics discovered with the use of 
such neuronal cells. these are not al-
lowed in patent law, but frequently found 
in material transfer agreements (MtAs). 
A typical example would be that an 
heSC line is transferred and all rights are 
claimed to all derivatives of these lines, 
e.g. with certain reporter constructs, or 
even to the constructs themselves if they 
have been developed with help of the 
cell line. Such claims do not usually de-
rive from patented intellectual property 
rights, but they are purely private agree-
ments fixed in the MTA. With regards to 
patenting inventions, based on other pat-
ented inventions (e.g. a new toxicologi-
cal test system based on the use of pat-
ented heSC cultures), there is no basic 
rule preventing this – indeed this is com-
monplace and independent of whether 
the basic patent was licensed or not. this 
situation has to be distinguished from the 
frequently found situations that indeed 
many technologies and tools applied to 
heSC are patented (media, growth fac-
tors, plasmids, constructs, …), and if 
the researcher employs or even wants to 
commercialize these, license agreements 
will become necessary.
4. 13  Issue 28: Secondary 
interests
the discussion of ethical aspects of eSC 
research would be incomplete without 
considering that certain groups use the 
discussion for their own purpose and 
goals, which may have nothing to do 
with heSC themselves. Alternative mo-
tives for rejecting heSC research may 
be the gain of voters and supporters for 
politicians and fundamentalist religious 
movements. Also a general technopho-
bia would be a motivation that is resist-
ant against any type of argument. On 
the other hand heSC research may also 
be promoted not for its own sake, but to 
improve career chances and income of 
certain scientists and doctors. 
5   A broader view
Human eSC are only one type of stem 
cells. If they can be easily substituted, 
why take the trouble, and why get ex-
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5.3  Issue 31: Technological 
alternatives: cells obtained 
during pre-implantation 
diagnostics
It may be interesting to review also other 
alternatives for generating pluripotent 
stem cells (Johnson, 2008). One approach 
stems from the area of pre-implantation 
genetic diagnosis (PIGD or PGD). When 
the zygote has divided 3 times and it 
reaches the 8-cell state (see Fig. 1), all 
eight cells are still totipotent and usu-
ally would form one embryo. However, 
each individual cell (called a blastomere) 
alone would be sufficient for full devel-
opment. therefore, when the Morula 
splits accidentally at this time, monozy-
gotic twins would form. It is nowadays 
technically possible to remove one of the 
blastomeres for PGD without destroying 
the embryo or inhibiting its development 
to a human being. In some countries, 
this procedure is used for genetic diag-
nosis and early sex determination, which 
bears huge ethical problems, in particular 
in countries like China (thomas, 2006). 
this technology is legally forbidden in 
some countries, including Germany.
It was recently shown in mice that a 
blastomere could be removed to generate 
an eSC line at this early stage, and the 
embryo continued to developed (Chung 
et al., 2006, teramura et al., 2007). Simi-
larly, it was shown that a heSC line could 
be generated from an individual human 
blastomere (Klimanskaya et al., 2006), 
and moreover it was shown for a human 
8-cell morula that a heSC line can be 
generated, while development of the em-
bryo goes on at least to blastocyst stage 
(Chung et al., 2008). this technology 
clearly avoids a lot of objections against 
the classical way of generating heSC. As 
the embryo is not killed, it may indeed 
be ethically acceptable to the Catholic 
Church, if it is proven that the chances 
for a successful pregnancy are not re-
duced by this method. this is, however, 
not clear at the present state of art, as the 
procedure requires poking a hole into the 
zona pellucida. therefore, such embryos 
thaw e.g. with more problems after hav-
ing been frozen. One may ask why one 
should run the danger of jeopardizing 
the life of a wanted child, while millions 
of blastocysts are available in nitrogen 
tanks. Another concern (which is about to 
the clear fact that adult stem cells (dif-
ferent from the hematopoietic system) 
have a limited growth and differentiation 
potential, a lot of erroneous information 
has been spread throughout the literature 
on the apparent global therapeutic use-
fulness of adult stem cells (Smith et al., 
2006). For instance, it has been claimed 
that bone marrow and hematopoietic 
cells may “trans-differentiate” to form 
other cell types not within their normal 
developmental lineage. However, it has 
been shown that such findings were, at 
least in parts, artifacts (Nygren et al., 
2004). Also, it has been demonstrated 
that adult stem cells are inefficient, or in 
some cases even dangerous, in settings 
where heSC-derived cells looked prom-
ising (Breitbach et al., 2007; Kolossov et 
al., 2006). A more recent concern is, that 
the potential of adult stem cells may be 
even more limited than believed earlier. 
For instance in the intestine, the tissue 
if formed by different, non-overlapping 
stem cell populations (Sangiorgi and 
Capecci, 2008). the most advanced 
area of adult stem cell use at the mo-
ment concerns so-called mesenchymal 
stem cells, multipotent (not pluripotent) 
stem cells that may form bone, cartilage 
and connective tissue. there exist ample 
sources for these cells, e.g. from fat tis-
sue obtained by liposuction, so that in 
vitro amplification is less of a problem. 
Also adult neural stem cells are being ex-
plored for the formation of neural tissue. 
In this case, availability of the cells is a 
seriously limiting factor, as is also true 
for cells from pancreas to heal diabetes, 
or cardiac muscle stem cells for heart 
repair. except for bone marrow trans-
plants which have a firmly established 
place in the repair of bone marrow, the 
present state of the art of stem cell appli-
cations can best be described as a race of 
different rescue teams in a very difficult 
landscape. All teams (heSC, fetal stem 
cells, adult stem cells, etc.) use different 
approach strategies and are still very far 
from the spot of the accident. So far, and 
with so many difficulties in between, it 
cannot be decided who will make it at 
all. In this situation, it appears unwise 
to exclude one of the important teams 
(heSC) early in the hope that the others 
may make it.
precursor cells, because they can only 
form a few cell types within their natural 
lineage. In fact, bone marrow transplan-
tations have been performed as early as 
1959 by a team lead by e.D. thomas, and 
this procedure represents the oldest form 
of stem cell therapy. 
Another more recently harnessed 
source of “adult” stem cells is the cord 
blood at birth. Hematopoietic cells 
from cord blood have indeed proven 
beneficial, especially for restoration of 
the blood-forming system (Broxmeyer, 
2005). Although this area is still in its 
infancy (Schoemans et al., 2006) com-
mercial companies have developed a 
flourishing business model based on the 
moral pressure on parents to have cord 
blood from their newborns frozen. this 
situation is an ethical issue in itself, as 
nobody knows in how far these cells can 
still be used in 70 years time, when they 
may be needed. These cells are difficult 
to expand (one requires currently more 
than one cord blood specimen to treat one 
diseased adult), they have a limited po-
tential (currently they are only useful to 
treat hematological malignancies – such 
as leukemia) or bone marrow failure –, 
and it is unclear whether treatment with 
own cord blood cells is always a good 
solution to treat genetic disease, as these 
cells are likely to carry the same muta-
tions that induced the disease. 
the use of the above adult stem cells 
for therapy has been quickly progressing 
because clinical trials can be performed 
without requiring FDA approval when 
cells are not greatly modified and when 
they are used to substitute tissue within 
their natural differentiation line (autolo-
gous transplants). For instance, when 
cells are cultured for less than 24 h before 
their homologous clinical use (e.g. bone 
marrow stem cells used as bone marrow 
substitute), the procedure is not regulated 
as a drug but as a surgical procedure by 
the FDA. However, adult stem cells that 
need to be expanded in vitro and modi-
fied fall under the same stringent rules as 
heSC, and their application has been very 
limited. As adult stem cells are far more 
limited in their potential to divide (in 
contrast, hESCs can divide indefinitely), 
production of large amounts, in addition 
to all the required safety examinations, 
is a serious technical obstacle. Despite 
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al., 2008; Wernig et al., 2007). How the 
oncogenes and their vectors (the viral 
gene fragments carrying the genes into 
the cells) behave on the long run, and 
whether the genetic stability is the same 
as in heSC will need to be established. 
With iPS cells, we deal with a potential 
alternative to heSC, which needs to be 
observed closely and which would re-
solve many of the ethical issues about 
present heSC. Perhaps, reprogramming 
can be achieved in the future with the 
corresponding proteins directly (instead 
of the genes) and thus, more safely. If the 
potential of iPS cells holds true, we are 
dealing with a medical and technological 
revolution that may bring the second No-
bel price to the field (after the one given 
2007 to M. Capecci, O. Smithies and M. 
evans) and heSC may become nothing 
more than a short, intermediary – but 
crucial – chapter in the history book of 
science.
5.5  Issue 33: Nuclear transfer 
and … human cloning
Cloning is the horror word of the field, 
although its everyday application is fairly 
innocent. Cloning means nothing more or 
less than copying something in a biologi-
cal system. Putting plant cuttings into the 
ground and growing blackberries from 
them is for instance a cloning progress. 
What people are afraid of is cloning of 
human beings, and this fear has led to 
objections to assisted reproductive tech-
nologies (e.g. in vitro fertilization), gene 
technology, biotechnology, and now 
heSC research. All of these have been 
wrongly associated with human cloning 
and it has not been stated clearly enough 
that it is at present technically impossible 
to clone a human (reproductive cloning), 
even if one wanted to. It will therefore 
not be dealt with further here as it has 
been discussed extensively elsewhere 
(Maio, 2006; tannert, 2006).
However, a technique sometimes called 
therapeutic cloning can play a role in the 
hESC field. Therapeutic cloning is a mis-
leading circumscription of a biological 
technique correctly called somatic cell 
nuclear transfer (SCNt). this technique 
starts from an oocyte which is in a state of 
being about to be fertilized, i.e. a cell with 
a high potential to develop further into 
genes coding for the proteins Oct4, Sox2, 
c-Myc, Klf4. these four proteins are 
known transcription factors (i.e. regula-
tors of gene expression themselves) that 
are highly expressed in heSC and are all 
well-characterized indicator for pluripo-
tency in heSC. Obviously, the procedure 
was only possible because of the ex-
tensive experience with the handling of 
stem cells and the profound knowledge 
on their control. iPS cells could never 
have been generated without previous 
heSC research, and the experience with 
human heSC was the basis for the recent 
production also of human iPS (takahashi 
et al., 2007; Yu et al., 2007). Although 
this is a milestone in stem cell research, 
it is important not to forget that for the 
generation of these cells, new genes are 
being expressed, and at least two of them 
are oncogenes (cancer-inducing genes), 
although later on it was shown that one 
of the oncogenes, c-Myc, is in fact dis-
pensable in the generation of iPS cells 
(Nakagawa et al., 2008), and most recent 
data from the Smith and Schöler labora-
tories indicate, that possibly only Oct4 is 
absolutely required. However, one needs 
to consider that the genes are integrated 
into the genome of iPS cells, which may 
pose a risk as this can theoretically disrupt 
the function of other genes. therefore, a 
long-term goal of some laboratories is to 
generate cells that transiently express the 
crucial pluripotency genes and then dif-
ferentiate these cells as long as they are 
pluripotent (Nakagawa et al., 2008). 
Obviously, it will still take a while 
until it is clear whether the iPS cells can 
ever be used therapeutically and whether 
all the reprogramming is indeed correct. 
Within the picture of itUNeS: some of 
the own song files that are moved back 
to the store, may be modified (possibly 
contain a virus or deletions), and some of 
the new songs downloaded for the stem-
ness library, may have been modified in 
the meantime by the store (e.g. not be 
available anymore, or be only available 
in a different version or recording). Up to 
now, this method appears very promising 
on different levels: It was shown that the 
markers of heSC and iPS were more or 
less identical (lowry et al., 2008; Wernig 
et al., 2007), and that at least murine iPS 
could be used therapeutically and form 
germ line cells and chimaeras (Hanna et 
become reality already now) is that nor-
mal fertile couples may chose this tech-
nology of assisted reproduction without 
direct need (Johnson, 2008), and mainly 
in order to provide their child to-be-born 
or sibling with a heSC line to provide 
“spare parts” that may be required later.
5.4  Issue 32: Generation of stem 
cells by re-programming: iPS
Reprogramming is the buzz-word of the 
year. What does this concept imply, how 
can we imagine differentiation and dedif-
ferentiation? Since it was shown that cer-
tain adult cells could be de-differentiated 
(re-programmed) to behave like heSC in 
2006 (takahashi and Yamanaka, 2006), 
this concept has had a profound impact 
on the stem cell field. This is because this 
method could provide a way to generate 
heSC-like cells without requiring blasto-
cysts, and moreover, autologous (“own”) 
heSCs could, in theory, be generated 
from each individual for own therapy 
(Cyranoski, 2008). 
to understand the re-programming, 
let’s try to understand the process of cel-
lular programming and of “stemness”. 
the genome could be seen to contain a 
large number of “songs” (of genes). this 
is like the itUNeS store. However, not 
all of these songs are active. Only a de-
fined set is usable. This is like the indi-
vidual itUNeS library. each type of dif-
ferentiated cell (a neuron, a heart cell, a 
liver cell, …) is like a particular itUNeS 
library on your computer or iPOD. like-
wise, eSC do not have all songs avail-
able, but again a defined set. This set of 
songs defines that they are stem cells 
and not other cells. thus, their particular 
iTUNES library defines their “stemness”. 
Re-programming of a somatic cell (=of 
any cell in the body which is not a stem 
cell) is like sending one’s entire itUNeS 
library back to the store and then down-
loading the set of songs that defines 
“stemness” as new library. 
It was indeed shown first for murine 
cells in the lab of Shinya Yamanaka that 
reprogramming of mouse skin cells to 
eSC-like cells is possible  (takahashi 
and Yamanaka, 2006). these cells were 
called induced pluripotent stem cells 
(iPS) and were obtained by the simple 
genetic transfer and expression of four 
Leist et aL.
Altex 25, 3/08186
cally matched) without ever touching the 
classical embryo stage, provided enough 
oocytes were available. However, the 
SCNt is associated with ethical and tech-
nical problems which are entirely unre-
lated to the cloning aspect. there is no 
unlimited availability of human oocytes 
and the oocytes themselves are heavily 
protected in many legislations. Oocytes 
and sperm are so-called gametes, and e.g. 
in Germany strict rules apply to handling 
and modification of gametes (embryo 
mimics the state of “post-fertilization”, the 
zygote may start to divide and grow and 
eventually form a blastocyst (French et al., 
2008). theoretically, heSC lines could be 
created at this stage, but have not yet been 
reported. Possibly, the technology will 
not develop further. If the iPS technology 
holds what it promises, it will be easier to 
apply than SCNt.
the advantage of this technology 
would be that heSC lines may be gen-
erated for each individual (immunologi-
totipotent and then multipotent cells, but 
with a nucleus that has only half the nor-
mal set of chromosomes and needs to fuse 
with a sperm nucleus to become complete 
again. One can circumvent the require-
ment for fertilization and fusion by re-
moving the oocyte nucleus and inserting a 
complete nucleus from an adult cell (from 
a skin cell for example) with the full chro-
mosome sets. this way, something “like a 
zygote” is created without fertilization. If it 
is brought into a culture environment that 
Box 1: Glossary of terms and abbreviations
Blastocyst: “Early embryo”, thin-walled hollow structure with 
about 200 cells containing the ICM (inner cell mass) and an outer 
rim. The blastocyst as a whole is totipotent, but its individual cells 
in the ICM are pluripotent. 
Blastomere: One of the 8 totipotent cells of the early (8 cell 
stage) embryo.
Chromosomes: Long threats of DNA. They contain all 
genetic information. Each human cell contains 23 different 
chromosomes. Somatic cells always contain two sets (2 x 23 
= 46) of chromo-somes (maternal and paternal). Gametes only 
contain one set.
Cryopreservation: A process of preserving and storing cells 
(such as oocytes, sperm, or blastocysts) by freezing them, 
typically at minus 196 degrees Celsius in liquid nitrogen.
DNA: Nucleic acid coding the “genetic information” by a code 
based on the sequence of 4 different chemical structures  
(= nucleotides).
Embryo proper: Parts of the blastocyst that form the real 
embryo; other parts form e.g. the placenta.
Epigenetics: Biological changes or information which is not 
encoded in the nucleotide sequence of the DNA. E.g. changes in 
gene expression (and protein content) induced by environmental 
factors, such as the position of a cell within an organism, by 
toxins or drugs.
FDA: Food and Drug Administration, agency in the US responsible 
for the safety regulations of foods, drugs, vaccines, etc.
Gametes: Oocytes and sperm are gametes, i.e. cells that can 
recombine to create the first cell of a new organism. Gametes 
differ from somatic cells in that they usually only contain one set 
of chromosomes.
Gastrulation: An early phase in embryo development that leads 
to the formation of the initial primordial tissues.
GMP: “Good Manufacturing Practice”, a term that stands for a high 
standard of control during the manufacturing of foods and drugs.
hESC: Human embryonic stem cells.
ICM: Inner cell mass, pluripotent cells within a blastocyst, which 
form the “embryo proper” and from which hESC can be derived.
In vitro: In cell culture, in a plastic dish, or in a test tube as 
opposed to in vivo (in an organism).
iPS cells: Induced Pluripotent Stem cells, somatic cells that 
were rendered pluripotent by the introduction of certain factors.
IVF: In vitro fertilization, a method to fertilize oocytes outside the 
body, followed by re-implantation of the early embryo.
Mesenchymal stem cells: Multipotent stem cells that can form 
bone, cartilage and connective tissue.
Morula: Early embryo, round blackberry-shaped solid cell mass, 
surrounded by the zona pellucida, emerging several days post-
fertilization, developmental stage preceding the blastocyst.
Multipotency: Capacity to form a set of different cells (e.g. all 
blood cell types), but not all cell types.
Nidation: Implantation of the early embryo (blastocyst) into the 
womb.
Nucleus: Structure of the cell where the chromosomes (genetic 
information) are stored.
Oligopotency:Capacity to form some closely related cell types 
(e.g. B and T lymphocytes), but not all cell types, e.g. in an organ.
Oocyte/Ovum: “Egg”, a cell carrying one set of chromosomes 
from the mother and the capacity to develop to an embryo when 
it fuses with sperm.
Pluripotency: Pluripotent cells can form any known cell type 
such as liver cells, muscle cells, neurons etc., but they cannot 
generate a whole organism because they are lacking the 
capacity to form a placenta.
Reprogramming: Induction of epigenetic changes in a somatic 
cell, to transform it into a stem cell. The somatic cell obtains 
“stemness”, but the DNA remains the same.
Somatic cell: Cells forming all the tissues of an organism and 
containing usually two sets of chromosomes, as opposed to 
germ line cells (gametes) that contain one set and are the basis 
for sexual reproduction.
Stemness: The characteristics that define a stem cell, i.e. of an 
undifferentiated cell that is able to multiply indefinitely and that is 
at least multipotent (can differentiate into other cell types).
Totipotency: Only a zygote and the blastomeres of the early 
embryo (up to 8-cell stage) have the capacity to form all know 
cells types as well as a whole organism, as these cells are able 
to form a placenta.
Zona pellucida: A membrane structure surrounding the early 
embryo from zygote to late blastocyst stage, degenerates around 
day 10 post-fertilization to facilitate nidation.
Zygote: Fertilized egg (oocyte), a cell carrying the genetic 
information of the oocyte plus the sperm (n=2).
Leist et aL.
Altex 25, 3/08 187
exclusively in natural ways, according 
to an ancient biological program. Now, 
many new technologies related to the 
early phase of this program are arising, 
with potential benefits, but also huge 
risks for misuse. ethical dilemmas do 
not only arise from different viewpoints 
within one society, but also from the 
largely differing legislations in neighbor-
ing countries. For instance bovine-human 
chimeric clones were legally produced in 
the UK, while such a process would be 
unthinkable, even for pure human clones 
in middle european countries. 
The embryo definition is highly prob-
lematic already, but it will become even 
more complicated in the future. For in-
stance, oocytes can theoretically develop 
without fertilization, if their nucleus is 
triggered appropriately. that this proc-
ess of so-called parthenogenesis works 
also in practice, is seen in many plant and 
animal species, but not naturally in mam-
mals. However, Japanese researchers 
have already created Kaguya, a fatherless 
mouse, that breeds normally (Moore and 
Ball, 2004). In 2004, a Korean researcher 
produced a parthenogenic human embryo 
by accident, as revealed only three years 
later, when an American group published 
the intentional production of purely par-
thenogenic human stem cells (Revazova 
et al., 2007, 2008). If such cells are used 
to generate blastocysts, is this an embryo? 
The definition of the fusion of the gam-
etes becomes useless in this case.
Another issue for the near future is the 
generation of gametes from heSC. As 
heSC are multipotent, it is just a matter of 
time until high quality gametes (oocytes 
and sperm) can be generated in a robust 
way. We have seen ways (issues 31, 32 
and 33) to produce heSC or cells that 
closely resemble them (iPS) by methods 
that do not use embryos (blastocysts) and 
thus should not be of the same ethical 
concern as classical heSC. What if gam-
etes are produced from such cells and 
they are used for fusion with one another 
to generate a zygote? How would we 
handle the definition of parents in these 
cases? How would we handle cross-ferti-
lization between different heSC lines by 
this method, to generate new lines with 
new genetic properties, some of them 
important as disease models, others also 
with a potential for misuse?
ation of embryo quality for implantation 
in the IVF procedure. Some embryos are 
judged to be of too poor quality to estab-
lish pregnancy. (However, in Germany 
it is not allowed anymore to undertake a 
positive or negative selection at the em-
bryo stage. the selection must have tak-
en place at the pronucleus-stage.) New 
methods allow generation of heSC from 
such embryos (lerou et al., 2008a,b). 
this procedure should reduce the ethical 
concerns of those objecting to heSC line 
generation, but the situation is too new to 
have been thoroughly discussed. It needs 
to be mentioned again (as detailed above) 
that also frozen embryos that have been 
used in the past for heSC generation 
were only used after informed consent of 
the donors and often because they were 
of poorer quality than the blastocysts 
used for induction of pregnancy. the rea-
son for their generation was IVF (and not 
research) and they were eventually used 
because they were not wanted anymore 
for implantation – and thus had no poten-
tial to ever develop to a human being.
A dilemma of the reverse form can 
be created, when the embryo definition 
is changed without adaptation of other 
rules affected by it. For instance in Swit-
zerland, a recent law ascribes full embryo 
status to zygotes only 24 h after fertili-
zation. this has strange consequences 
on the generation of heSC. Zygotes that 
were frozen years ago (before this law 
was passed), cannot be used for the gen-
eration of cell lines anymore, as they now 
are by definition no embryos anymore. 
By thawing them and keeping them in 
the culture dish, they would reach an 
age of 24 hours and then be considered 
to be embryos generated for research. 
A related situation is found in Scotland. 
there, failed oocytes (with no potential 
to develop) can be used for research. If 
such an oocyte is fertilized to generate a 
heSC line, this line is ethically unaccept-
able in most other countries, because its 
source has been an embryo “generated 
for research”.
5.7  Issue 35: Problems to come
ethical problems related to heSC are 
only the tip of an iceberg if one takes all 
the new developments into account. Un-
til last century, humans were procreating 
protection law), which also explicitly 
prohibits cloning. In the UK, even the 
use of animal oocytes is allowed as re-
cipients for human nuclei. the product, 
which is termed “human-animal chime-
ras” was legalized in May 2008. Howev-
er, the use of such chimaeras is restricted 
to a defined set of applications in basic 
science. the different legislations, even 
within the eU, demonstrate how ethical 
issues are judged differently in its mem-
ber countries. 
5.6  Issue 34: Playing  
with definitions to generate 
alternatives
the above chapters (31, 32 and 33) dem-
onstrate that rapid developments of tech-
nology can create new problems faster 
than they can be resolved in an ethical 
debate. therefore, some scientists tried to 
solve the issues by technical approaches. 
Whether this is really a way out of the di-
lemma or rather a dead end remains open. 
However, the example of altered nuclear 
transfer illustrates well the complexities 
of the ethical debate and the problems 
that arise when one sticks too closely to 
definitions. 
Altered nuclear transfer is one of a 
number of ways that have been designed 
to produce cell lines without the require-
ment of potentially viable zygotes (= 
“embryos”). One such approach is the in-
troduction of a genetic defect preventing 
implantation, into an oocyte. For instance 
a defect in the gene for Cdx-2 prevents 
development of the embryo (Meissner 
and Jaenisch, 2006). A zygote could be 
formed, but clearly lack the potential to 
ever become a human being. A heSC line 
may thus be derived from such a disabled 
pre-embryo without any danger of “em-
bryo consumption” or “embryo killing”. 
Although this is a scientifically elegant 
approach, it is not free of ethical concerns 
(because for instance an oocyte is being 
used, and in particular genetic manipula-
tion of oocytes is forbidden in some coun-
tries) and the procedure is dangerously 
close to a slippery slope of double moral 
and political correctness that can end in 
complete ethical confusion without bring-
ing a significant practical benefit. 
An approach that appears more realis-
tic is based on the morphological evalu-
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